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Abstract

The overall objective of this thesis was to evaluate the antimicrobial effects of four
novel broad-host-range antimicrobial agents. The first was a milk-derived lipoprotein
developed by Westgate Biologicals with the support of Enterprise Ireland. This
lipoprotein which was designated LactiSAL, was evaluated against a wide range of
bacterial species associated with humans. Essentially, the LactiSAL was incorporated
at a variety of concentrations into agar media, which were appropriate for cultivation
of the different genera. Agars were examined for colony formation, after which it was
possible to quantify the minimal

inhibitory concentration for each genus.

Subsequently, LactiSAL was incorporated at levels close to the minimal inhibitory
concentration (MIC) into early log phase broth cultures for each genus. Optical
density and bacterial titres were monitored throughout the growth cycle. The results
indicated that the lipoprotein brought about lysis of bacterial cells, as evidenced by a
reduction in optical density and a reduction in bacterial titre. This was confirmed by
assays for leakage of the intracellular enzyme Lactate Dehydrogenase (LDfl).
Concentrations in the range of 0.1 to 0.4% LactiSAL were sufficient to inhibit Gram
positive bacteria, whereas levels of 2.0% or greater were necessary to inhibit Gram
negatives. Various physical factors influencing its activity were recorded. The
LactiSAL was also evaluated in the porcine gastrointestinal tract environment at
levels dictated by Westgate Biologicals. The antimicrobial effect was significantly
reduced in this environment and this is thought to have resulted from the degradative
activity of digestive-tract enzymes. The second part of this thesis focussed on Cyclic
dipeptide:

Cyclo-(L-Leu-L-Pro);

Cyclic

dipeptide:

Cyclo-(L-Phe-L-Pro)

and

Phenyllactic Acid. These three low molecular weight antimicrobial agents are
naturally produced by Lactobacillus plantarum FSTL7. Initial antimicrobial assays
were performed with the producer strains on neutralized MRS agar. These were

followed up by studies with ehemically synthesized pure forms of each of the three
compounds. The approach for antimicrobial assays in this case used was broadly
similar to that used for LactiSAL. As with lactiSAL, these agents were evaluated
against a wide range of bacterial genera and its inhibitory levels were defined. The
study confirmed that all four compounds have a broad inhibitory spectrum which
includes Gram-positive and -negative bacteria and also fungi.

Section 1

Literature review

This literature review is divided into two parts. Part / is a comprehensive review of
antimicrobial agents with particular emphasis on the classes that are studied in this
MSc research project. Part II is a review of the knowledge on the various
microorganisms encountered in this project

1.1 Antimicrobial agents

1.1.1 Introduction to antimicrobials

An antimicrobial is a substance that kills or inhibits the growth of microbes such as
bacteria (antibacterial aetivity), fungi (antifungal activity), viruses (antiviral activity),
or parasites (anti-parasitic activity). Antimicrobial agents are frequently exploited by
man to eliminate problematic microorganisms. The modern era of western
antimicrobial therapy began in 1929 with Fleming’s discovery of the powerful
bactericidal substance penicillin with broad antimicrobial activity (Fleming 1929). In
the early 1940s, spurred partially by the need for antibacterial agents in the second
World War, penicillin was isolated, purified and injected into experimental animals,
where it was found to not only cure infections but also to possess incredibly low
toxicity for the animals. This fact ushered into being the age of antibiotic
chemotherapy and an intense search for similar antimicrobial agents of low toxicity to
animals proving useful in the treatment of infectious disease. The most important
property of an antimicrobial agent, from a host point of view, is its selective toxicity
(i.e the agent acts in some way that inhibits/kills bacterial pathogens but has little or
no toxic effect on the host). This implies that the biochemical processes in the bacteria
are in some way different from those in animal cells, allowing for these differences to
be exploited.

In order for an antimicrobial agent to take effect, it must remain in the active form,
reach the target, achieve sufficient levels at the target and deprive the bacterial eell of

some essential substance or function. This review will focus on antimicrobial agents
which occur naturally in biological systems (Levy 1994). A diverse range of
macromolecules and low-molecular-weight compounds can act as antimicrobial
agents. The high molecular weight structures include bacteriocins (proteins)
bacteriophages (protein with nucleic acid enclosed), fatty acids and lipoproteins
(protein combined with lipid). Low molecular weight molecules include classical
antibiotics, organic acids, cyclic dipeptides, aroma compounds produced by lactic
acid bacteria (e.g diacetyl) and hydrogen peroxide (Piard and Desmazeaud 1991,
1992, Ouwehand 1998). In the following sections the above antimicrobials are
reviewed.

1.1.2 Bacteriocins

Bacteriocins are peptide antibiotic agents which are encoded by the genetic material
often associated with plasmid DNA. Their effect is the killing or inhibition of closely
related bacterial species or even different strains of the same species. Genes encoding
resistance to bacteriocins are always present in the producer strains to ensure that the
producer is not harmed (Cleveland et al 2001). Resistance is governed by the
immunity protein, encoded by the inim gene, which in many cases masks the cellsurface receptor for bacteriocin action. Bacteriocins are usually named after the
species in which they are produced (Ross et al 2002). Bacteriocins were first
discovered by Gratia in 1925 (Gratia 1925) who was at the time engaged in the search
for methods of eliminating infectious bacteria. In fact, he is also associated with early
work in the use of bacteriophages as antimicrobial agents. He called his first
bacteriocin a colicin because it killed E. coli. Bacteriocins are thought to arise from

the need for bacterial survival in an over-populated environment or culture. Thus,
cells containing a plasmid encoding a bacteriocin have the capability of destroying
surrounding cells without the bacteriocin plasmid. The event is compensated by the
rate at which the bacteriocin containing cell is able to transfer the plasmid encoding
the bacteriocin-producing function into other closely-related cells. Eventually, only
cells containing a plasmid encoding the bacteriocin, will be left in existence. The
majority of bacteriocins differ from traditional antibiotics in one critical way: they
have a relatively narrow killing spectrum and are therefore toxic only to bacteria
closely related to the producing strain (Cleveland et al 2001). Accordingly, they can
be considered "designers drugs" which target specific bacterial pathogens.

Considerable work has been done to date on

the mode of action and potential

applications of bacteriocins (and genetically-modified bacteriocins) to solve some of
the most challenging problems in infectious disease control and this work has been
reviewed several times recently (Ross et al 2002, Beijeaud and Cenatiempo 2004, Nes
et al 2007). The most exploited bacteriocin to date is Nisin, which is produced by the
Gram-positive Lactococcus lactis and it has been approved for use as a preservative in
food systems since the 1930s (Taylor et al 2007). Another much studied bacteriocin is
the previously mentioned colicin, which is encoded by the Col plasmids, and as
expected, originated in the bacterial species, Esherichia coli. Colicins funetion by
disrupting the cell membrane of surrounding Esherichia cells which lack the
immunity protein. As with most well studied bacterioeins, the result is leakage from
the cell of potassium ions and protons, causing an inability to generate energy,
resulting in cell-death (Diez-Gonzalez 2007, Cascales et al 2007).

1.1.3 Bacteriophages

A bacteriophage is a virus whieh infeets bacteria. Like all viruses, it is non-living and
hijacks the bacterium's metabolie maehinery and energy to produce progeny phage
until the bacterium is destroyed and phage is released to infect surrounding bacteria
(Coffey and Ross 2002). Bacteriophage, allowing invasion of a cell, have the ability
to integrate their genome into the bacterial host chromosome provided the required
DNA sequences are present in the host ehromosome. In this state, the bacteriophage
genome is preserved indefinitely, and this is the mechanism which guarantees
bacteriophage survival in nature. Under certain conditions, the bacteriophage genome
can excise and undergo the so-called lytie cycle, resulting in replication of the phage
DNA and development of progeny bacteriophage particles, which are released
following disruption of the bacterial cell by two baeteriophage-encoded lytic
enzymes. I'hese enzymes are the holin (which generates holes in the phospholipid
membrane) and lysin (a muramidase which degrades the cell wall, located outside the
phospholipid membrane) (O’Flaherty et al 2005b). Bacteriophage often enter the lytic
cycle directly after infection and such bacteriophage are referred to as lytic phage.
This generally occurs when genetic sequences required for bacterial chromosomal
integration are not present in the bacterium being infected. It is worth mentioning that
phages have been identified which are apparently incapable of integration into any
bacterial host chromosome. These exelusively-lytic bacteriophages have considerable
potential

as

antibacterial

agents

(O’Flaherty

et

al

2004,

2005a,

2005b).

Bacteriophages, like bacteria, are very common in all natural environments and are
directly related to the spectrum of bacteria present. They are very common in soil and

other bacteria-rich environments and have played a significant role in shaping the
evolution of bacteria (O’Flaherty et al 2004). Frederick Twort (1915) and Felix
d'Herelle (1917) were the first to publish a report on viruses which infect bacteria,
which d'Herelle called bacteriophages (eaters of bacteria) (Sulakvelidze and Morris
2001). In the 1930s and subsequent decades, pioneering virologists such as Luria,
Delbruck and many others utilized these viruses as model systems to investigate many
aspects of virology, including virus structure, genetics, replication, etc. These
relatively simple agents have been very important in the development of our
understanding of all types of viruses, including those of man, which are much more
difficult to propagate and study (Greer 2005).

The application of bacteriophages as antimicrobials (called phage therapy) has been
taken for granted in the former Soviet Union (FSU) States since their identification
and impressive level of characterization by D’Herelle (Summers 1999). Much of the
research publications on phage therapy from the FSU suggest that the bacteriophages
are highly effective at eliminating infectious bacteria. However, the research results in
these publications, particularly the earlier ones, were frequently poorly-controlled and
many research descriptions did not appear to follow the scientifie standards common
in research in Europe and in the USA (Sulakvelidze and Morris 2001). Nevertheless, a
recent large, well-controlled and very comprehensive study on phage therapy by the
Polish Academy of Sciences strongly suggests that the application of phages as
antimicrobial agents is potentially highly effective (Borysowski et al 2005). Thus, the
research topic has received renewed attention given the emergence of antibiotic
resistant infectious bacteria (O’Flaherty, 2005a). The early highlights of phage
therapy research are well described in the biography of Felix D’Herelle (Summers,

1999). The recent developments and successes in using phage as antimicrobial agents
have been reviewed recently by Sulakvelidze (2005). In addition, the exploitation of
phage-encoded lytic enzymes for pathogenic streptococci (Fischetti 2005) and MRSA
(O’Flaherty et al 2005b, Borysowski et al 2006) has considerable merit for
consideration as potential antibacterial agents for controlling antibiotic-resistant
infectious bacteria.

1.1.4 Fatty acids

A fatty acid is a carboxylic acid often with a long unbranched aliphatic tail (chain),
which is either saturated or unsaturated. Carboxylic acids as short as butyric acid (4
carbon atoms) arc considered to be fatty acids, while fatty acids derived from natural
fats and oils may be assumed to have at least 8 carbon atoms, e.g. caprylic acid
(octanoic acid). Most of the natural fatty acids have an even number of carbon atoms,
because their biosynthesis involves acetyl-CoA, a coenzyme carrying a two-carbonatom group (Nelson and Cox 2004). Fatty acids are produced by the hydrolysis of the
ester linkages in a fat or biological oil (both of which are triglycerides), with the
removal of glycerol. With regard to antimicrobial activity, medium-chain free fatty
acids and their corresponding 1-monoglycerides have been found to have a broad
spectrum of microbicidal activity against enveloped viruses (Isaacs et al 1995, Kabara
1978, Shibasaki and Kato 1978, Thormar et al 1987, Welsh et al 1979), including
pathogens like herpes simplex virus (Kristmundsdottir et al 1999), and also various
bacteria such as Neisseria gonorrhoea, Chlamydia trachomatis (Bergsson et al 1998),
group A streptococci, group B streptococci (GBS) and Staphylococcus aureus
(Bergsson et al 1999). The mechanism by which these lipids kill bacteria is not
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known, but electron microscope studies indicate that they disrupt cell membranes
(Bergsson et al 1998). Antimicrobial lipids are commonly found in natural products,
for example milk, and are therefore likely to be nontoxic to mammalian mucosal
membranes, at least at low concentrations. Nevertheless, in milk interfacing with
mucosal membranes, these compounds are considered to be potent inhibitors of many
human pathogens and parasites (Isaacs et al 1994, 1995). Antimicrobial fatty acids
have also been described dry fermented sausage (Sanz et al 1988) and fermented milk
products (Rao and Reddy 1984).

The antimicrobial activity of fatty acids has been recognized for many years. The
unsaturated fatty acids are active against Gram-positive bacteria and fungi. The
antifungal activity of fatty acids is dependent on chain length, concentration, and pH
of the medium (Gould 1991). The antimicrobial action of fatty acids has been thought
to be due to the undissociated molecule, not the anion, since pH had profound effects
on their activity, with a more rapid killing effect at lower pH (Kabara 1993). While
immunoglobulins in mammalian milk are linked to antimicrobial activity, milk does
contain a number of antimicrobial factors which are not immunoglobulins (Falkler et
al 1975, Fieldsteel 1974, Matthews et al 1976, Sarkar et al 1973). Some of these
factors are located in the nonlipid fraction of milk, but most studies have found
antimicrobial activity associated with the lipid fraction (Thormar et al 1987).
Research on antimicrobial properties of milk-associated fatty acids began in the 1930s
and 1940s (Bayliss 1936, Kodicek 1949, Winslow and Lochridge 1906, Reid 1932,
Bergeim 1940). Nieman comprehensively summarised the early work in 1954
(Nieman 1954) and proposed a connection between dietary fat and resistance to
infectious diseases, though none of the previous researchers had used natural fats in

their experiments. Not until the late 1970s did researchers show that the antimicrobial
action of milk-fat depended on the presence of lipase (Welsh et al 1978, Welsh et al
1979, Isaacs and Thormar 1991, Isaacs et al 1995, Glas and Schaafsma 1988) to
release the free fatty acids (FFAs) and monoglycerides (MGs) (Kabara and Vrable
1977, Parodi 1997, Sun et al 2002). The bactericidal activity of fatty acids depends on
their nature, e.g., chain length, and on the bacterial strain involved (Bibel and
Shinefield 1992, Coonrod and Yoneda 1983, Kabara et al 1972). Generally, Gram
positive bacteria are lipid sensitive whereas Gram-negative bacteria are not (Kabara et
al 1972, Petschow et al 1996, Petschow et al 1998).

1,1.5 Lipoproteins

A lipoprotein is a biochemical assembly that contains both protein and lipid. The
lipids or their derivatives may be covalently or non-covalently bound to the proteins.
Many enzymes, transporters, structural proteins, antigens, adhesins and toxins are
lipoproteins (Babu and Sankaran 2002). Examples include the high density and low
density lipoproteins of the blood, the transmembrane proteins of the mitochondrion
and the chloroplast and bacterial lipoproteins (Babu et al 2006,). The lipids are often
an essential part of the complex, even if they seem to have no catalytic activity in
themselves (Babu and Sankaran 2002).

The dramatic increase in antibiotic resistance in bacteria has prompted research to
increase the arsenal of antimicrobial agents. Several new drugs have emerged as
possible therapeutic alternatives (Cormican and Jones 1996, Gonzalez et al 2003,
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Raad et al 1998, Woodford 2005). Among the compounds that are currently under
investigation for their therapeutic potentials are antimicrobial peptides and
lipopeptides of the innate immune system and their synthetic derivatives. Widely
distributed in nature, antimicrobial peptides are an essential defense component of
invertebrates and vertebrates and control cell proliferation and invading pathogens
(Cannon 1987, Hancock 2001, Hancock and Chappie 1999).

Numerous studies of synthetic peptides have focused on designing analogue peptides
with antimicrobial activities, more potent than those of the natural peptides, w'ithout
damaging mammalian cells. Several attempts have been made to improve the
antimicrobial activities of these lipo-pcptides against bacterial cells while eliminating
the cytotoxicity against mammalian cells, such as red blood cells, by changing the
llexible-region chain length and changing the net charge and hydrophobicity and/or
helicity (Bpand and Vogel 1999, Putsep et al 1999, Steiner et al 1981). Short
lipopeptides are monomeric in solution, while longer ones form oligomers; and this
feature can potentiate the killing of microbes (Avrahamid and Shai 2004, Malina and
Shai 2005). So far, different mechanisms of bactericidal activity have been identified.
One of these, the best understood, is mediated by the direct disruption of bacterial
membrane potential, which results cell death. Such antimicrobial agents are less likely
to result in the development of cross-resistance in the target bacterium. Other reports
have provided evidence that some lipopeptides are capable of killing bacteria via
interference with synthesis of the cell wall (Makovitzki and Shai 2005, Malina and
Shai 2005).
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1.1.6 Antibiotics

Antibiotics have been the most widely-used antibacterial agents in medieal practiee
since the 1940s (Roberts 1998). Antibiotics are low-molecular weight substances that
are produced as secondary metabolites by certain groups of microorganisms,
especially Streptomyces, Bacillus, and molds {Penicillium and Cephalosporium). The
success in applying antibiotics for eliminating infections over the past fifty years
began with Fleming’s discovery of Penecillin (Fleming 1929) and ultimately led to
the development of many artificial derivatives of natural antibiotics as resistance to
antibiotics emerged (Wiedemann 1997). These are semi-synthetic antibiotics which
are produced in some form by a microorganism and then chemieally modified to
improve antibiotic properties. Antibiotics may have bacteriocidal (killing) effects or a
bacteriostatic (inhibitory) effect on a range of microbes. The range of bacteria or other
microorganisms that is affected by a certain antibiotic is expressed as its spectrum of
action. Antibiotics effective against prokaryotes which kill or inhibit a wide range of
Gram-positive and Gram-negative bacteria are said to be broad-spectrum (e.g.
Tetracyclines) antibiotics. If effective mainly against Gram-positive (e.g. Penicillin)
or Gram-negative bacteria (Roberts 1998, Bhavnani and Ballow 2000), they are
narrow spectrum antibiotics (e.g. polymixins) and if effective against a single
organism or disease, they are referred to as limited spectrum. The great number of
diverse antibiotics currently available can be classified in different ways by their
chemical structure, their microbial origin, or their mode of action (Roberts 1998,
Bhavnani and Ballow 2000).

Antibiotics achieve their antimicrobial effect by having a selective toxicity. They
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attack a process in the microorganism which has no counterpart in humans, such as
activity of the exclusively-prokaryotic 70S ribosome, another example is bacterial cell
wall synthesis. In this context, the antibiotic penicillin prevents the cross linking of
small peptide chains in peptidoglycan, the main wall polymer of bacteria. Pre-existing
cells are unaffected, but all newly produced cells grow abnormally, unable to maintain
their wall rigidity, and they are susceptible to osmosis (Wiedemann 1997). A wide
variety of commercially-available antibiotics exist today, and these have had an
immense impact on human health in recent decades. Unfortunately their wide-spread
usage world-wide has resulted in the emergence of problematic antibiotic-resistant
bacteria (Cormican and Jones 1996, Gonzalez et al 2003, Raad et al 1998, Woodford
2005).

1.1.6.1 Resistance to Antibiotics

Resistance to antimicrobial agents is recognized at present as a major global public
health problem. In the last 5 years, the World Health Organisation, the European
Union, The House of Lords (UK) (http://www.parliament.uk/lords/index.cfm) and the
Centre for Disease Control (USA) (http://www.cdc.gov), the National Disease
Surveillance Centre (Ireland) (http://www.ndsc.ie/hpsc) and many more agencies have
prepared reports on the scale of this problem. If unchecked, antimicrobial resistance
can be expected, at a minimum, to increase complications and costs associated with
complex therapeutic procedures and treatments. There is already evidence that in
hospital patients, infection by antibiotic resistant bacteria is associated with an
increase in mortality above that seen with infection with antibiotic susceptible
bacteria (Neu 1992). The repeated and continued use of antibiotics creates selection
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pressure, favoring the growth of antibiotie resistant mutants. The widespread use of
antibioties today is thought to have spurred evolutionarily adaptations that enabled
baeteria to survive these powerful drugs, other microbes such as viruses, fungi and
parasites have also developed resistance. Resistance to penicillin in some strains of
staphylococci was recognized almost immediately after the introduction of the drug.
Resistance to penicillin today occurs in as many as 80% of all strains of
Staphloccocus aureus. Some strains of S. aureus have been isolated that are resistant
to virtually all clinically available antibiotics (Peschel and Collins 2001).

At present, there is great concern that commensal bacterial populations from food and
the gastrointestinal tract (GIT) of humans and animals, such as lactic acid bacteria
(LAB) and bifidobacteria, could act as a reservoir for antibiotic resistance genes
(Ammor et al 2006). Resistances could ultimately be transferred to human pathogenic
and opportunistic bacteria, hampering the treatment of infections (Ammor et al 2006).
As plasmids are independent genetic elements of the cell chromosome, they do not
contain the vital genes for the bacteria. Although many plasmids have been
characterized as cryptic, i.e. very little is known about the properties they carry, it has
been observed that plasmids carry a wide variety of genes which are not housekeeping
genes. A major category of these are the antibiotic resistance genes: vital genes for
bacterial survival. Antibiotic resistance genes encode specialized proteins which
render the cell containing the resistant plasmid 'immune' to a particular substance
present in the cells environment, which would otherwise inhibit or destroy the cell.
Antibiotic resistance plasmids have been much studied for many reasons, one of
which is a result of harmful bacteria surviving antibiotics (Graz et al 2000). In natural
environments, antibiotics were substances produced by fungal microorganisms to
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eliminate competition by bacteria for survival reasons. Over time, and as a result of
evolution, plasmids have developed genes to which allow their existence in the
presence of selected antibiotics, and due to the transferrable property of plasmids
(Navashin and Sazykin 1998), the spread of resistance to an antibiotic is made more
efficient. Proteins produced from the antibiotic genes on the plasmid, may either
function to inactivate an antibiotic, or affect it’s uptake into the cell. One plasmid may
carry several resistant genes, rendering the cell resistant to more than one antibiotic
(flarbottle et al 2006). The antibiotic resistances conferred by plasmids broadly reflect
the agents commonly used against their bacterial hosts. Examples of antibiotics
bacteria have been discovered to be resistant to include: aminoglycosides, such as
streptomycin, chloramphenicol, fusidic acid, beta-lactam antibiotics such as penicillin,
ampicillin and carbenicillin, sulphonamides, tetracyclines and macrolides e.g,
erythromycin (Graz et al 2000). This widespread resistance to antibiotics, globally,
has given rise to a need for development of different (alternative) effective
antimicrobial agents (Harbottle et al 2006).

1.1.7 Organic acids

Fermentation by lactic acid bacteria is characterized by the accumulation of organic
acids and the accompanying reduction in pH. The levels and types of organic acids
produced during the fermentation process depend on the species of organisms, culture
composition

and

growth

conditions (Lindgren

and

Dobrogosz

1990).

The

antimicrobial effect of organic acids lies in the reduction of pH, as well as the
undissociated form of the molecules (Gould 1991, Podolak et al 1996). It has been
proposed that the low external pH causes acidification of the cell cytoplasm, while the
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undissociated acid, being lipophilic, can diffuse passively across the membrane
(Kashket 1987). The undissociated acid acts by collapsing the electrochemical proton
gradient, or by altering the cell membrane permeability, which results in disruption of
substrate transport systems (Smulders et al 1986, Earnshaw 1992). The acidprodueing properties of lactic acid bacteria is widely exploited for preservation of
foods such as cheese, yoghurt, salami, sauerkraut and sourdoughs (Caplice and
Fitzgerald 1999).

1.1.7.1 Lactic acid

Lactic acid is the major metabolite of the lactic acid bacteria (LAB) fermentation,
where it is in equilibrium with its undissociated and dissociated forms. The extent of
the dissociation depends on pH. At low pH, a large amount of lactic acid is in the
undissociated form, and it is toxic to many bacteria, fungi and yeasts. However,
different microorganisms vary considerably in their sensitivity to lactic acid. At pH
5.0, lactic acid was reported to be inhibitory toward spore-forming bacteria, but was
ineffective against yeasts and moulds (Woolford 1975). El-Gazzar et al (1987)
reported that it was possible to grow Aspergillus parasiticus NRRL2999 in a medium
containing 0.5 or 0.75% lactic acid at a pH of 3.5. Lindgren and Dobrogosz (Lindgren
and Dobrogosz 1990) showed that at different pH ranges, the minimum inhibitory
concentration (MIC) of the undissociated lactic acid was different against Clostridium
tyrohutyricum, Euterobacter sp. and Propionibacterium freudenreichii ssp. shermanii.
In addition, the stereoisomers of lactic acid also differ in antimicrobial activity, Llactic acid being more inhibitory than the D-isomer (Benthin and Villadsen 1995).

1.1.7.2 Acetic and propionic acids

Acetic and propoinic acids are produced by LAB strains through heterofermentative
pathways. Their antimicrobial action is though to result from their interaction with
cell membranes, causing intracellular acidification and protein denaturation (Huang et
al 1986). They are more antimicrobially effective than lactic acid due to their higher
pKa values (lactic acid 3.08, acetic acid 4.75, and propionic acid 4.87), and higher
percent of undissociated acids than lactic acid at a given pH (Earnshaw 1992). Acetic
acid was more inhibitory than lactic and citric acids toward Listeria monocytogenes
(Ahmad and Marth 1989, Richards et al 1995), and toward the growth and
germination of Bacillus cereus (Wong and Chen 1988). Acetic acid also acted
synergistically with lactic acid; lactic acid decreases the pH of the medium, thereby
increasing the toxicity of acetic acid (Adams and Hall 1988).

1.1.8 Hydrogen peroxide and carbon dioxide

1.1.8.1 Hydrogen peroxide

Hydrogen peroxide (H2O2) is produced by lactic acid bacteria in the presence of
oxygen, as a result of the action of flavoprotein oxidases or nicotinamide adenine
hydroxy dinucleotide (NADH) peroxidase. The antimicrobial effect of H2O2 may
result from the oxidation of sulfhydryl groups, causing denaturing of a number of
enzymes, and from the peroxidation of membrane lipids thus the increased membrane
permeability (Kong and Davison 1980). H2O2 may also be as a precursor for the
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production of bactericidal free radicals such as superoxide (O2') and hydroxyl (OH')
radicals which can damage DNA (Byczkowski, and Gessner 1988). It has been
reported that the production of H2O2 by Lactobacillus and Lactococcus strains
inhibited Staphylococcus aureus, Pseudomonas sp. and various psychotrophic
microorganisms in foods (Davidson et al 1983, Cords et al 1993). In raw milk, H2O2
activates the lactoperoxidase system, producing hypothiocyanate (OSCN-), higher
oxyacids (O2SCN- and O3SCN-) and intermediate oxidation products which are
inhibitory to a wide spectrum of Gram-positive and Gram-negative bacteria (Reiter
and Harnulv 1984, Conner 1993).

1.1.8.2 Carbon dioxide

Carbon dioxide is mainly produeed by heterofermentative lactic acid bacteria. The
precise mechanism of its antimicrobial action is still unknown. However, CO2 may
play a role in creating an anaerobic environment which inhibits enzymatic
decarboxylations, and the accumulation of CO2 in the membrane lipid bilayer may
cause a dysfunction in permeability (Eklund 1984). CO2 can effectively inhibit the
growth

of many

food

spoilage

microorganisms,

especially

Gram-negative

psychrotrophic bacteria (Farber 1991, Hotchkiss 1999). The degree of inhibition by
CO2 varies considerably between the organisms. CO2 at 10% could lower the total
bacterial counts by 50% (Wagner et al 1989), and at 20-50% it had a strong antifungal
activity (Lindgren and Dobrogosz 1990).
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LI.9 Aroma components

1.1.9.1 Diacetyl

Diacetyl is produced by strains within all genera of lactic acid bacteria which carry
out a citrate fermentation. The antimicrobial effect of diacetyl has been known since
the 1930s (Jay 1982). It inhibits the growth of Gram-negative baeteria by reacting
with the arginine-binding protein, thus affecting the arginine utilization (Jay 1982).
Jay (1982) showed that Gram-negative bacteria were more sensitive to diacetyl than
Gram-positive bacteria; the former were inhibited by diacetyl at 200 g/mL and the
latter at 300 g/mL. Diaeetyl at 344 g/mL inhibited strains of Listeria, Salmonella,
Yersinia, Escherichia coli, and Aeromonas. Since the production of diacetyl during
lactic fermentation is low, e.g. 4 g/mL produced by L. lactis ssp. diacetylactis (Cogan
1980), and the acceptable sensory levels of diacetyl are at 2-7 g/mL (Earnshaw 1992),
its practical use as a food preservative is limited. Mowever, diacetyl may act
synergistically with other antimicrobial factors (Jay 1982) and contribute to combined
preservation systems in fermented foods.

1.1.9.2 Acetaldehyde

Aeetaldehyde is produced by lactobaeilli, for example Lb. delbrueckii ssp. bulgaricus
by the aetion of a threonine aldolase, which cleaves threonine into acetaldehyde and
glycine. Since Lb. delbrueckii ssp. bulgaricus and S. thermophilus in yoghurt cannot
metabolize acetaldehyde, it accumulates in the product to a concentration of about 25
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ppm. Acetaldehyde at 10-100 ppm has been shown to inhibit the growth of
Staphylococcus aureus, Salmonella typhimurium and E. coll in dairy products (Piard
and Desmazeaud 1991).

1.1.10 Reuterin and other low-molecular-mass (LMM)
compounds
1.1.10.1 Reuterin

Reuterin is produced by Lb. reuteri, a heterofermentative species inhabiting the
gastrointestinal traet of humans and animals (Axelsson and Lindgren 1987). It is
formed during the anaerobic growth of Lb. reuteri by the action of glycerol
dehydratase which catalyzes the conversion of glycerol into reuterin (Talarico et al
1988).

Reuterin

has

been

chemically

identified

to

be

3-hydroxypropanal

(hydroxypropionaldehyde), a highly soluble pH-neutral eompound which is in
equilibrium with its hydrated monomeric and cyclic dimeric forms (Axelsson et al
1989, falarico and Dobrogosz 1989). The hydrated form, 3-Hydroxypropanal cyclic
dimer reuterin exhibits a broad spectrum of antimicrobial activity against certain
Gram-positive and Gram-negative bacteria, yeast, fungi and protozoa.

Figure 1.1 (overleaf). Reuterin, an antimicrobial from Lactobacillus reuteri, exists in
three forms in aqueous solution (from Talarico & Dobrogosz, 1989).
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Spoilage organisms sensitive to reuterin include species of Salmonella, Shigella,
Clostndium, Staphylococcus, Listeria, Candida and Trypanosoma (Axelsson et al
1989). Besides reuterin which has been well studied, there are several reports on the
production of LMM antimicrobial compounds by different species of LAB. NikuPaavola et al. (Niku-Paavola et al 1999) showed that Lb. plantarum V'fT E-78076
produced LMM compounds active against Pantoea agglomerans VTT E-90396 and
the fungus Fusarium avenaceum VTT D-80147. Other LMM compounds that have
been reported are often active at low pH and are heat stable with a broad spectrum of
activity (Ouwehand 1998). However, it is not clear whether the antimicrobial effects
are caused by these compounds or due to primary metabolites such as lactic and acetic
acids or hydrogen peroxide. Lortie and co-workers (1993) reported the production of
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LMM inhibitory substances by Lh. casei strains, the activity being possibly due to the
effects of small antibiotics, peptides, short-chain fatty acids and lactic acid. These
authors suggested that the final proof of the produetion of LMM antimicrobial
compounds must be the isolation and identification of these compounds.

1.1.10.2 Phenyllactic acid

Among the natural preserving systems, sourdough has long been known to improve
the shelf lives of bread and bakery products. Rocken (1996) observed that sourdough
antifungal activity was strictly related to acetie aeid production. More reeently, the use
of sourdough lactic acid bacteria to inhibit mold growth was studied, which led to the
identification of a strain of Lactobacillus plantarum 2IB, whose culture filtrate
showed a distinctive antifungal aetivity. Phenyllaetic aeid (PLA) was shown to be one
of the major compounds occurring in the culture, together with lactic acid and acetic
acid (Lavermicocca et al 2000). Dieleveux et al (Dieuleveux ct al 1998) isolated PLA
from a eulture filtrate of Geotrichum candidum and characterized it as the main
eompound responsible for the anti-LA/enV? activity shown by the fungal culture. These
authors obtained relevant inhibition of pathogen growth in an agar diffusion well assay
by using DL-PLA, while D-3-PLA inhibited the growth of Listeria monocytogenes
cultured in liquid medium and in ultrahigh-temperature (UHT) whole milk. It also
inhibited the growth of several strains oi Staphylococcus aureus, Escherichia coli and
Aeromonas hydrophila on solid medium (Dieuleveuxd and Gueguen

1998,

Dieuleveux et al 1998). PLA has been reported to be one of the most abundant
aromatic acids to which antibacterial properties have been attributed and to oeeur in
several honeys with different geographical origins (Steeg and Montag 1987, Weston
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et al 1999). The structure of PLA is shown on the opening page of Section 4 (Part II).

1.1.10.3 Cyclic Di-peptides

1.1.10.3.1 Characteristics

Cyclic dipeptides, also named 2,5-diketopiperazines, are among the simplest peptide
derivatives commonly found in nature (plants, fungi and bacteria). Most cyclic
dipeptides found to date appear to have emerged as by-products of fermentation and
food processing. However, many are endogenous to members of animal and plant
kingdoms; these include cyclo(Pro-Lcu), cyclo(Pro-Val), cyclo(Pro-Phe), cyclo(AlaLeu), cyclo(Pro-l yr), cyclo(Pro-Trp), and cyclo(His-Pro). Although the five cyclic
dipeptides cyclo(His-Pro), cyclo(Leu-Gly), cyclo(Tyr-Arg), cyclo(Asp-Pro), and
cyclo(Pro-Phe) exhibit interesting physiological and/or pharmacological activities in
mammals (Niku-Paavola et al 1999), only one of these, cyclo(His-Pro), has been
conclusively shown to be endogenous to mammals. On the other hand, cyclo(LeuGly), cyclo(Tyr-Arg), and cyclo(Asp-Pro) are structurally related to endogenous
peptides Pro-Leu-Gly-NH2 (melanocyte-stimulating hormone release inhibiting
factor), Tyr-Arg (kyotorphin), and Val-Pro-Asp-Pro-Arg (enterostatin), respectively,
and these may serve as precursor peptides. It still needs to be determined, however,
whether these peptides can indeed result from the processing of their respective
precursors.

Cyclic dipeptides are widely used as models for larger peptides because of their
simplicity and limited conformational freedom (Prasad 1995). Some cyclic dipeptides
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have been shown to be antiviral, antibiotic and anti-tumor. Niku-Paavola and co
workers carried out an experiment on the biological activity of four selected cyclic
dipeptides -cyclo(L-phe-L-prolyl, cyclo(L-tyr-L-prolyl), cyclo(L-try-L-prolyl) and
cyclo(try-L-try), the results from the assays indicated that the cyclic dipeptides have
biological activites in prokaryotes and eukaryotes (Niku-Paavola et al 1999). Three of
the dipeptides block cation channels and all increased the expression of the enzyme
alkaline phosphatase. All the dipeptides were found to have concentration dependant
antibacterial properties. The results suggested that with the increased solubility the
cyclic dipeptides may have potential as muscle relaxants, anti-tumor compounds and
antibiotics. (Milne et al 1998). Other biological activities reported for cyclic
dipeptides include involvement in bacterial quorum-sensing, inhibition of allatoxin
production and cell-differentiating effects (Strom 2002).

1.1.10.3.2 Cyclic dipeptides as a broad-spectrum antimicrobials

Historically, cyclic dipeptides have been known to possess the potential to affect a
large number of pertinent biological processes. The therapeutic potential of these
compounds reflects their antibiotic, antiviral and, anti-tumor properties and various
cyclic dipeptides are detectable in protein and polypeptide hydrolysates, as well as in
cultures of yeast, lichens and fungi. In 2004, Rhee (2004) investigated the combined
effects of cyclo(L-leu-L-prolyl) and cyclo(L-phe-L-prolyl) on the growth of
vancomycin-resistant enterococci (VRE) and pathogenic yeasts as well as determining
their anti mutagenic effects. It was reported that this drug combination was especially
effective against five VRE strains, namely Enterococcus faecium (K-99-38y), E.
faecalis (K-99-17), E. fciecolis (K-99-258) E. faecium (K-01-312) and E. Faecalis (k-
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01-511). In addition, the cyclic dipeptides were reported to exert anti-mutagenic
effects against Salmonella typhimurium TA98 and TAIOO strains in a Salmonella
mutation assay. The number of mutant colonies of S. typhimurium strains TA98 and
TAIOO induced by exposure to the mutagen AF-2 decreased in a concentration
dependant manner in the presence of the cyclic dipeptides (Rhee 2004).

In the overall context of this review, the results obtained demonstrate that the
combined drugs have anti-VRE, anti-bacterial and anti-yeast activities, and that it may
have significant potential as a broad spectrum anti-microbial. Mow the drug
combination increases anti-microbial activity is currently unknown, however, Graz
and co-workers (2000) reported that the antibacterial effect of the cyclic dipeptides
could be explained by the hydrophobic nature of the compounds, which could
interfere with the outer membrane (Gram negative) and plasma membrane (Gram
positive), fhe loss of function could result in a loss of cellular integrity, leading to
cell death (Milne et al 1998).

1.1.10.3.3 Bacterial sources of cyelic dipeptides and their function

One significant source of cyclic dipeptides is bacteria, for example lactic acid bacteria
(Strom et al 2005). Magnusson and co-workers described production of an aminoacid-based antifungal compound by a Lactobacillus coryniformis strain (Magnusson
et al 2003), while Lavermicocca et al (2003) reported isolation of the antifungal
compounds phenyllactic acid and 4-hydroxyphenyllactic acid from Lactobacillus
plantarum. As mentioned earlier, short-chain fatty acids, for example eaproic acid,
produced by the sourdough bacterium Lactobacillus sanfrancisco also exhibit anti
mold activities (Magnusson et al 2003). L. plantarum can also produce fungus-
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inhibitory low-molecular-weight substances, such as benzoic acid, methylhydantoin,
mevalonolactone, and cyclo-(Gly-L-Leu), while a fungistatic bacteriocin-like
substance, pentocin TV35b, can be isolated from a Lactobacillus pentosus strain
(Magnusson et al 2003). It is thought that the role of many of these compounds is
actually cell-cell communication, and the antimicrobial activity is coincidental.

Strom and co-workers (2005) reported for the first time in 2002, the production of the
antifungal cyclic dipeptides, cyclo (L-Phe-L-Pro) and cyclo(L-Phe-/ram-4-OH-LPro) from a Lactobacillus plantarum strain (MiLAB 393). L. plantanim (MiLAB 393)
was isolated from grass silage which is known to produce a broad spectrum of anti
fungal compounds active against food- and feed-borne filamentous fungi and yeasts,
fhree antifungal substances were produced by the L. plantarum strain; cyclo (L-PheL-Pro), cyclo(L-Phe-/ram'-4-OH-L-Pro) and 3-phenyl lactic acid, all three were
isolated and the structures were determined. The fungal inhibitory concentrations of
the antifungal compounds isolated in this work are thought to be high compared to
antifungal drugs, such as amphotericin B and nikkomycin Z, which inhibit fungal
growth at concentrations in the microgram-per-milliliter (pg/ml) range. The
antifungal activity of the isolated cyclic dipeptides is thought to most probably be a
secondary effect; the primary reason for production might instead be related to
quorum sensing or other unknown mechanisms. Nevertheless, the antifungal activity
of these substances is of considerable importance for the fungal inhibitory activity of
the bacterial strain MiLAB 393 in food systems. Further evaluation of LAB for
antifungal properties could lead to useful biopreservation systems, preventing fungal
spoilage and mycotoxin formation in both food and animal feed (Strom et al 2002,
Magnusson et al 2003).
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1.1.10.3.4 Bacterial cyclic dipeptides and cell-cell communication

Cell-to-cell communication in bacteria via chemical signal molecules has been
intensively studied in the past decade, leading to an appreciation of the wide variety
of mechanisms and overlapping systems bacteria use to communicate with each other
and coordinate

population-dependent gene expression. This phenomenon

is

commonly referred to as quorum sensing (QS) and has probably been best
characterized in the Vibrio spp by Klose (2006). Several different QS pathways have
been elegantly characterized in Vibrio fischeri, V. harveyi, and V. cholerae\ these
pathways modulate bioluminescence, biofilm formation, and pathogenesis (Klose
2006). I he cell-cell signaling mechanism in Gram-negative bacteria occurs via the
production and response to a class of small diffusible molecules called Nacylhomoserine lactones (AHLs). This quorum sensing style of communication is
responsible for the regulation of several physiological processes and many virulence
factors in pathogenic bacteria. The detection of these molecules has been rendered
possible by the utilization of genetically-engineered bacterial biosensors which
respond to the presence of exogenously supplied AHLs (Degrassi et al 2002). Holden
and co-workers (1999) described the purification, structural identification and
chemical synthesis of a family of cyclic dipeptides identified as having antifungal,
anti-tumor activity and antibacterial activity. These are diketopiperazines (DKPs),
from cell-free supernatants of Pseudomonas aeruginosa and other Gram-negative
bacteria. The biological significance of these cyclic dipeptides as putative signal
molecules is discussed below with evidence presented to show that these compounds
are capable of activating or antagonizing lux-based AHL biosensors and AHL-

29

dependent swarming in Serratia liquefactions (Holden et al 1999, Klose 2006).

In cell-free Pseudomonas aeruginosa culture supernatants, Holden and co-workers
(1999) identified two compounds capable of activating an N-acylhomoserine lactone
(AHL) biosensor. Mass spectrometry and NMR spectroscopy revealed that these
compounds were not AHLs but the diketopiperazines (DKPs), cyclo(DAla-L-Val) and
cyclo(LPro-L-Tyr) respectively. These compounds were also found in cell-free
supernatants from Proteus mirabilis,

Citrobacter freundii and Enterobacter

agglomerans [cyclo(DAla-L-Val) only]. Although both DKPs were absent from
Pseudomonas fuorescens and Pseudomonas alcaligenes, a third DKP, which was
chemically

characterized

as

cyclo(L-Phe-L-Pro)

was

isolated,

from

both

pseudomonads. Dose response curves using a LuxR-based AHL biosensor indicated
that cyclo(DAla-L-Val), cyclo(L-Pro-L-Tyr) and cyclo(L-Phe-L-Pro) activate the
biosensor in a concentration-dependent manner, albeit at much higher concentrations
than the natural activator N-(3-oxohexanoyl)-L-homoserine lactone (3-oxo-C6-HSL).
Competition studies showed that cyclo(DAla-L-Val), cyclo(L-Pro-L-Tyr) and
cyclo(L-Phe-LPro)

antagonized

the

3-oxo-C6-HSL-mediated

induction

of

bioluminescence, suggesting that these DKPs may compete for the same LuxRbinding site. Similarly, DKPs were found to be capable of activating or antagonizing
other LuxR-based quorum-sensing systems, such as the N-butanoylhomoserine
lactone-dependent swarming motility of Serratia liquefaciens. Although the
physiological role of these DKPs has yet to be established, their activity suggests the
existence of cross talk among bacterial signalling systems (Holden et al 1999). This
provides evidence that these DKPs are either synthesized de novo from the products
of primary metabolism or generated via the metabolism of bacterially generated
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peptides. Although cyclo(DAla-L-Val) has not previously been identified as a natural
product, two of the compounds identified in this study by Holden, namely cyclo(LPhe-L-Pro) and cyclo(L-Pro-LTyr), have recently been isolated during a search for
novel antibacterial agents from an Antarctic sponge-associated P. aeruginosa strain
(Niku-Paavola 1999, Strom et al 2002). Both cyclo(L-Phe-L-Pro) and cyclo(L-Pro-LTyr) have been shown to possess significant phytotoxic activity on spotted knapweed.
Additionally, a derivative of cyclo(L-Phe-L-Pro), cyclo[L-(4-hydroxyprolinyl)-LPhe], has been shown to act as plant growth promoter. A number of DKPs have also
been shown to elicit pharmacological effects in humans and other mammals.
However, only cyclo(L-His-L-Pro) has been unequivocally identified in mammalian
tissues. This DKP and cyclo(LPhe-L-Pro) and cyclo(L-Pro-L-Tyr) have been shown
to act on the central nervous system, where they modulate a remarkable range of
behaviour (Matthew et al 1999). Degrssi and co-workers (2002), using diverse
bacterial biosensors, purified several biosensor activating fractions by organic
extraction, HPLC and TLC of cell-free culture supernatants of plant growthpromoting Pseudomonas putida WCS358. Surprisingly, it was observed that the most
abundant compounds in these fractions were cyclic dipeptides or diketopiperazines,
which at the time was a novel finding in Gram-negative bacteria. The purification,
characterization, chemical synthesis of four DKPs were reported and identified as
cyclo(L-Pro-L-Tyr), cyclo(L-Pro-L-Leu), cyclo(L-Phe-L-Pro) and Cyclo(L-Val-Leu)
(Degrassi et al 2002).

Degrassi’s research highlights the production of DKP by Gram-negative bacteria but
the functioning of these molecules is still largely undercharacterized. Nevertheless the
study demonstrates that DKP are also present in P. putida and highlights that the
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molecules are probably widely produced by Gram-negative bacteria. Degrassi et al.
stated that understanding these molecules which are produced by Gram-negative
bacteria could prove very important for understanding gene expression of virulence
factors of many Gram-negative pathogens. Degrassi and co-workers stated that the
involvement of DKP in quorum sensing adds to the plethora of potential functions of
these intriguing molecules (Degrassi et al 2002).

In addition to the above research in Gram-negative bacteria, four Streptomyces
species, namely Streptomyces scabies, Streptomyces acidiscahies, Streptomyces
turgidiscahies and Streptomyces ipomoeae (described as the causal agents of scab
disease affecting economically important root and tuber crops worldwide), produce a
family

of

cyclic

dipeptides-

the

thaxtomins-

cyclo-(L-4-nitrotryptophyl-L-

phenylalanyl) and related congeners, which mimic disease symptomatology (Frank et
al 2000).

Ocean sponges have proved to be a source of cyclic dipeptides, many of which are
believed to constitute a chemical defense against predators or foulers aimed at
protecting the body surface. Two brominated cyclo dipeptides have been reported
(Klose 2006) in the marine sponge Geodia barretti Bowerbank and are compounds
that strongly inhibit the settlement of the barnacle larva of Balanus improvisus and the
blue mussel Mytilus edulis. The brominated cyclodipeptides barettin (cyclo [(6bromo-8-entryptophan)

arginine])

and

8,9-dihydrobarettin

(cyclo

[(6-

bromotryptophan) arginine]) isolated from the marine sponge Geodia barretti have
been shown to inhibit settlement of barnacle larvae in a dose-dependent manner in
concentrations ranging from 0.5 to 25 pM. To further establish the molecular target
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and mode of action of these compounds (Hedner et al 2006). Hedner investigated their
affinity to human serotonin receptors. I’he tryptophan residue in the barettins
resembled that of endogenous serotonin [5-hydroxytryptamine]. A selection of human
serotonin receptors, including representatives from all subfamilies (Prasad 1995
Benedetti et al 1976, Sletten 1969, Hedner et al 2006, Frank et al 2000, Lucietto et al
2006, Dal Bello et al 2001), were transfected into HEK-293 cells. Barettin selectively
interacted

with

the serotonin

receptors

5-HT2A,

5-HT2C,

and

5-HT4

at

concentrations close to that of endogenous serotonin, 8,9-Dihydrobarettin interacted
e.xclusively with the 5-HT2C receptor and it failed to show affinity to 5-HT2A and 5HT4, indicating that the double bond between the tryptophan and arginine residue
plays an important role in the interaction with the receptor proteins.

Mender and co-workers (2006), also identified the marine cyclic dipeptides barettin
and 8-9 dihydrobarettin as selective serotonin receptor ligands, suggesting that this
information may be further useful in the defining of the functional roles of 5-HT
receptors in invertebrates. The slight difference in chemical backbone between
barettin and 8,9-dihydrobarettin results in the striking differences in affinity to the
human 5-HT receptors, also suggesting a possible function for these compounds as
templates to provide clues in drug discovery research, aimed at disease states
associated with the serotonergic system.

1.1.10.3.5 Conformation of Cyclic Dipeptides

Bendetti et al (1976) solved the structures of six N-methylated diketopoiperazines
derived from alanine, valine, and phenylalanine. The optically active isomer of
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cyclo(N-methyl-L-alanyl), its racemate cyclo(N-methyl-L-valyl) and cyclo(N-methylL-phenylalanyl) were found to assume boat conformations with axial substituents on
the Carbon atoms. The meso isomers, cyclo (N-methylL-valyl-N-methyl-D-valyl) and
cyclo (N-methyl-L-phenlalanyl-N -methyl-D-phenylalanyl) were found to assume
chair structures with axial dispositions of the substituents on the caron atoms
(Bendetti et al 1976). Structure investigations were undertaken to notify any
conformational aspects could explain the observed differences in hydrolysis rate
between DL and LL isomers of cyclic dipeptides. The structures of Cyclo-D-alanyl-Lalanyl and Cyclo-L-alanyL- alanyl were determined using crystal X-ray anaysis. The
DL molecules were found to be almost planar, while the LL molecule was found to be
appreciably puckered, adopting a skewed boat conformation with the methyl
substituents quasi-equatorial. Einar suggested that the difference n the conformation
might account for the difference in the hydrolysis rate between DL and LL isomers
(Sletten 1969). Conformation of Cyclic Dipeptides-The Folding of Cyclic Dipeptides
Containing an Aromatic Side Chain.The folding of peptide chains is determined by
non-bonded interactions among the side chains of the amino acid residues and by the
geometry of covalent and hydrogen bonds. In principle, peptide folding could be
completely determined for each case by X-ray crystallographic analysis, but is
unlikely that it can be done for any peptide or protein of interest. Kopple used proton
magnetic resonances of a number of cyclic dipeptides, with and without an aromatic
acid residue and found that the preferred conformation of the aryl methyl side chain is
one in which the aromatic ring faces the dipeptide (DKP) ring (Kopple and Marr
1967).
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1.1.10.3.6
Enzymatic conversion of cyclic dipeptides to dehydro derivatives
that inhibit cell division

A Streptomyces albidus KO-23 (Albonoursin producing) strain was found to catalyse
the conversion of several cyclic dipeptides having Phe and aliphatic side chaincontaining amino acid residues to the corresponding dehydro derivatives. Among the
dehydro cyclic dipeptides prepared, tetrahdeydro exhibited inhibitory activity toward
the first cleavage of sea urchin, while dehydro did not. It was previously found that
cyclo(Leu-Phe) and its dehydro derivitives did not show any inhibitory activity, in
contrast to high activity in the case of Albonoursin. Together these findings indicate
that dehydrogenation at the alpha-beta positions of both amino acid residues in this
particular cyclic dipeptide is required for the inhibitory activity (Kanzaki et al 2000).

1.1.10.3.7 Cyclic dipeptidcs in the induction of maturation for cancer therapy

In cancer research, studies have suggested a possible therapy based on the use of
maturation-inducing compounds to induce differentiation of neoplastic cells and
stimulate more rapid recovery of the normal cell population after tumour elimination,
fhe study of the effects of nine cyclic dipeptides on biochemical markers of
differentiation implicated their potential to induce differentiation (Graz et al 2000).
Studies have been undertaken to determine the specificity of these agents for HT-29
cell cultures as well as the identification of the signal transduction pathways affected
by these agents, inducing the differential gene expression observed in the ceils. The
cyclic dipeptides studied showed a high degree of specificity, having no significant
effect on Caco-2 cells (P>0.05), representing the normal gastrointestinal mucosa. All
inducers administered were shown to affect the total energy state of HT-29 cells, an
effect which increased the probability of HT-29 cell differentiation. Results indicated
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that those agents, which induced differential gene expression, acted at different steps
in the isolated signal transduction pathway. Cyclo(Trp-Trp) and cyclo(Phe-Pro)
induced a high degree of acetylation of histones (P<0.05), while the remaining cyclic
dipeptides induced a high degree of phosphorylation of histones (P<0.05) (cycio(TrpTrp) induced a moderate degree of histone phosphorylation). The results from histone
phosphorylation and acetylation, and cyclic AMP responsive element binding protein
phosphorylation studies, suggested that the cyclic dipeptides activated a chromatin
switch, which leads to the increase in accessibility of lineage-specific genes for
transcription (Degrassi et al 2002, Graz et al 2000).

1.1.11 Conclusion

This review has focused mainly on novel and interesting low molecular weight
compounds which may be exploited as antimicrobial agents. Other antimicrobial
agents have been discussed for completeness but in less detail. The dramatic increase
in antibiotic resistance in bacteria has prompted research to increase the arsenal of
antimicrobial

agents.

Since

the

identification

of

penicillinase-producing

Staphylococcus aureus in the 1940s, many pathogens have proven themselves adept at
developing or acquiring mechanisms that confer resistance to all clinically available
antibacterial classes. As discussed in this review, several new antimicrobial agents
have emerged as possible therapeutic alternatives. Many of these require further
scientific studies before they can be fully exploited to eliminate problematic
microorganisms.
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1.2 Microorpanisms encoimtered in this project
The following is a concise review of the knowledge on the various microorganisms
used in this project. Where relevant, their role in infectious disease is included.

12.1 Lactobacillus
Lactobacillus is a genus of Gram-positive, facultative anaerobic bacteria. They are a
major part of the lactic acid bacteria group, named as such because most of it’s
members convert lactose and other sugars to lactic acid. They are common and
usually benign. In humans, they are present in the vagina and the gastrointestinal tract,
where they are symbiotic and make up a small portion of the gut flora. Many species
are prominent in decaying plant material. The production of lactic acid makes its
environment acidic which inhibits the growth of some harmful bacteria. Several
members of the genus have had their genome sequenced. Lactic acid bacteria are
found in many nutrient rich environments and occur naturally in various food
products such as dairy and meat products, and vegetables (Carr et al 2002). They have,
by tradition, been established as a natural, consumer and environment friendly way of
preserving food and feed. The preserving effect is
mainly due to the reduction of pH, through the
production of lactic acid. Besides lactic acid,
several antimicrobial compounds arc produced
during growth of LAB (Lindgren and Dobrogosz
1990).

Figurel.2 Electron microscope image of Lactobacillus plantarum.
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122Bifidobacterium
Bifidobacterium is a genus of Gram-positive, non-motile, often branched anaerobic
bacteria. Bifidobacteria are one of the major genera of bacteria that make up the gut
flora, the bacteria that reside in the colon. Bifidobacteria aid in digestion, are
associated with a lower incidence of allergies (Bjbrkstcn et al 2001) and also prevent
some forms of tumor growth (Guarner and Malagelada 2003). Some bifidobacteria are
being used as probiotics. Bifidobacteria, called probiotics, arc a natural part of the
bacterial flora in the human body and have a symbiotic bactcria-host relationship with
humans. B. longiim promotes good digestion, boosts the immune system, and
produces lactic and acetic acid that controls intestinal pH. These bacteria also inhibit
the growth of Candida albicans, E. coli, and other bacteria that have more pathogenic
qualities than Bifidobacteria.

Figure 1.3 Electron microscope image of Bifidobacterium adolescentis This
beneficial bacterium is found in some dairy products such as yogurt
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123 Enterococcus
Enterococcus is a genus of lactic acid bacteria of the phylum Firmicutes. Members of
this genus were classified as Group D Streptococcus until 1984, when genomic DNA
analysis indicated that a separate genus classification was appropriate (Schleifer and
Kilpper-Balz 1984). Enterococci are Gram-positive cocci which often occur in pairs
(diplococci) and are difficult to distinguish from Streptococci on physical
characteristics alone. Two species are common commensal organisms in the intestines
of humans: E. faecalis (90-95%) and E. faecium (5-10%). Enterococci are facultative
anaerobic organisms, i.e. they prefer the use of oxygen, but they can survive in the
absence of oxygen. They typically exhibit gamma-hemolysis on sheep's blood agar.
Important clinical infections caused by Enterococcus include urinary tract infections,
bacteremia, bacterial endt>carditis, diverticulitis, and meningitis. Sensitive strains of
these bacteria can be treated with ampicillin and vancomycin (Fischetti ct al 2000).
Figure 1.4 (a) Enterococcus sp. infection in pulmonary tissue (b) Scanning electron
micrograph of Enterococcus faecium - Gram-positive, VRE, coccus prokaryote
(dividing); causes skin and wound infections.

I
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1.2.4 Streptococcus
Streptococcus is a genus of spherical shaped Gram-positive bacteria, belonging to the
phylum Firmicutes and the lactic acid bacteria group. They test positive for oxidase
and negative for catalase (Ryan et al 2004). Cellular division occurs along a single
axis in these bacteria, and thus they grow in chains or pairs, thus the name — from
Greek streptos, meaning easily bent or twisted, like a chain. Contrast this with
staphylococci which divide along multiple axes and generate grape-like clusters of
cells (Facklam 2002). In addition to strep throat, certain Streptococcus species are
responsible for many cases of meningitis, bacterial pneumonia, endocarditis,
erysipelas and necrotizing fasciitis (the 'flesh-eating' bacterial infections). It should be
noted, however, that many streptococcal species are non-pathogenic. Streptococci arc
also part of the normal commensal flora of the mouth, skin, intestine and upper
respiratory tract of humans.

Figure 1.5 (a) Strep throat is caused by the genus Streptococcus (b) Scanning electron
micrograph of oral bacterium Streptococcus mutans.
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1^.5 Clostridium
Clostridium is a large genus of Gram-positive bacteria, belonging to the Firmicutes.
They are obligate anaerobes, capable of producing cndosporcs. Individual cells arc
rod-shaped, which gives them their name, from the Greek kloster or spindle. These
characteristics traditionally defined the genus, but they are not phylogenetically
significant, and many species originally classified as Clostridium have been moved
elsewhere. Clostridium includes common free-living bacteria as well as important
pathogens. There arc four main species responsible for disease in humans (Ryan and
Ray 2004, Wells and Wilkins 1996). C. hotulinum, an organism producing a toxin in
food that causes botulism. C. difficile, which can overgrow other bacteria in the gut
during antibiotic therapy, can cause pseudomembranous colitis. C. perfritigens, causes
a wide range of symptoms, from food poisoning to gas gangrene. Also responsible for
cntcrotoxcmia (also known as "overeating disease" or "pulpy kidney disease") in
sheep and goats. C. tetani, the causative organism of tetanus (lockjaw).

Figure 1.6 (a) Endoscopic visualization of pseudomembranous colitis, a characteristic
manifestation of full-blown Clostridium difficile colitis, (b) Scanning electron
micrograph of C.difficle.
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12,6 Staphylococcus aureus
Staphylococcus is a genus of Gram-positive bacteria. Under the microscope they
appear round (cocci), and form in grape-like clusters. Staphylococci can cause a wide
variety of diseases in humans and other animals either through toxin production or
invasion. Staphylococcal toxins are a common cause of food poisoning (Ryan and
Ray 2004). The bacteria grow in improperly stored food. Although the cooking
process kills them, the enterotoxins are heat resistant and can survive boiling for
several minutes. Staphylococci can grow in foods with relatively low water activity
(such as cheese and salami). One pathogenic species is Staphylococcus aureus, which
can infect wounds. These bacteria can survive on dry surfaces, increasing the chance
of transmission. Of this type, Methicillin-resistant Staphylococcus aureus (MRSA)
has recently become a major cause of hospital-acquired infections and is being
recognized with increasing frequency in community acquired infections. Any ,V.
aureus infection can cause the staphylococcal scalded skin syndrome, a cutaneous
reaction to exotoxin absorbed into the bloodstream. It can also cause a type of
septicaemia called pyaemia (Holt 1994).

Figure 1.7 (a) Skin infection caused by Staphylococcus aureus (b) Electron
microscope image of Staphylococcus aureus. Electron micrograph from Visuals
Unlimited, with permission.
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U.7 Listeria
lAsteria is a bacterial genus containing six species. Named in honour of Joseph Lister,
lAsteria species are Gram positive bacilli and are typified by L. monocytogenes, the
causative agent of Listeriosis (Ryan and Ray 2004). lAsteria monocytogenes is a
bacterium commonly found in soil, stream water, sewage, plants, and food. Each
bacterium is Gram-positive and rod-shaped. lAsteria are known to be the bacteria
responsible for listeriosis, a rare but lethal food-borne infection that has a devastating
mortality rate of 25% (Salmonella, in comparison, has a less than 1% mortality rate).
They arc incredibly hardy and able to grow in temperatures ranging from 4°C, the
temperature of a refrigerator, to 37°C, the body's internal temperature. Furthermore,
listerosis's dcadlincss can be partially attributed to the infection's ability to spread to
the nervous system and cause meningitis. Finally, lAsteria has a particularly high
occurrence rate in newborns because of its ability to infect the fetus by penetrating the
endothelial layer of the placenta (Tinlcy ct al 1989).

Figure 1.8 (a) Listeria monocytogenes escaping from infected cells in comet-like
structures, (b) Electron microscope image of lAsteria monocytogenes.
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1^.8 Mycobacterium
Mycobacteria arc usually considered Gram-positive and they do not contain
cndosporcs or capsules. Mycobacterium smegmatis is an acid-fast bacterial species in
the genus Mycobacterium. It was first reported in November 1884, by Lustgarten,
who found a bacillus with the staining appearance of tubercle bacilli in syphilitic
chancres. Subsequently, Alvarez and Tavcl also found organisms similar to that
described by Lustgarten in normal genital secretions (smegma). This organism was
later named M. smegmatis (Cole ct al 1998). M. smegmatis is generally considered a
non-pathogcnic microorganism, however, in some cases it can cause disease, mainly
in animals. Both leprosy and tuberculosis, caused by Mycobacterium leprae and
Mycobacterium tuberculosis respectively, have seriously plagued mankind for
centuries. With the emergence of antibiotic resistant strains of tuberculosis, research
into mycobacteria has become all the more important in combatting these modern
mutants of ancient pathogens (Ryan and Ray 2004).

Figure 1.9 (a) Mycobacterium avium complex (MAC) infection (human lung).
Secondary infection to AIDS, HIV. (b) Electron microscope image of Mycobacterium
pa ratu b ercii losis.
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12.9 Enterobacter
Enterohacter is a genus of common Gram-negative, facultatively-anaerobic, rod
shaped bacteria of the family Enterobacteriaceae. Several strains of the these bacteria
are pathogenic and cause opportunistic infections in immunocompromised (usually
hospitalized) hosts. The urinary and respiratory tract are the most common sites of
infection. Enterobacter can be distinguished from other GNR by virtue of being a 'fast
fermenter' of lactose. Enterohacter sakazakii is a bacterium belonging to the family
Enterobacteriaceae, which contains a number of bacterial species found in the human
and animal gut and the environment. The microorganism has been implicated in
outbreaks causing meningitis or enteritis, especially in infants (Roberts et al 1999,
Harald and Roggenkamp 2003). In the few outbreaks reported, 20% to >50% of the
infants who contracted the disease died. For survivors, severe lasting complications
can result, including neurological disorders. The outcome related to adult disease
seems to be significantly milder.
Figure 1.10 Electron microscope image of Enterobacter sakazakii.
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1^.10 Bacteroides
Hacteroides is a genus of Gram-negative, rod-shaped bacteria. Bacteroides species are
non-endospore-forming, anaerobes, and may either be motile or non-motile,
depending on the species. The DNA base composition is 40-48% GC. Unusual in
bacterial organisms, Bacteroides membranes contain sphingolipids. They also contain
meso-diaminopimelic acid in their peptidoglycan layer. Bacteroides species also
benefit their host by excluding potential pathogens from colonizing the gut. Some
species {B. fragilis, for example) are opportunistic human pathogens, causing
infections of the peritoneal cavity, gastrointestinal surgery, and appendicitis, via
abscess formation, inhibiting phagocytosis, and inactivating beta-lactam antibiotics.
Bacteroides arc generally resistant to a wide variety of antibiotics-bcta-lactams,
aminoglycosides,

and

recently,

many

species

have

acquired

resistance

to

erythromycin and tetracycline. This high level of antibiotic resistance has prompted
concerns that Bacteroides species may become a reservoir for resistance in other,
more highly pathogenic bacterial strains (Salyers ct al 2004, Madigan ct al 2005).

Figure 1.11. Electron microscope image of Bacteroides fragilis.
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1^.11 Escherichia coli

Escherichia is a genus of Gram-negative, non-spore forming, facultatively anaerobic,
rod-shaped bacteria from the family Enterobacteriaceae. Inhabitants of the
gastrointestinal tracts of warm-blooded animals, Escherichia species provide a portion
of the microbially-dcrived vitamin K for their host. Escherichia coli arc the most
numerous aerobic commensal inhabitants of the large intestine in humans. While
many Escherichia arc harmless commensals, particular strains of some species arc
human pathogens, and arc known as the most common cause of urinary tract
infections, (Ronald 2003) significant sources of gastrointestinal disease, ranging from
simple diarrhea to dyscntcry-likc conditions, as well as a wide-range of other
pathogenic states. While E. coli is responsible for the vast majority of Escherichiarclatcd pathogenesis, other members of the genus have also been implicated in human
disease (Picn ct al 1985, Chaudhury ct al 1999)
Figure 1.12 (a) Edema disease is a result of release of the verotoxin SLT-II variant
during enteric infection by some serotypes of Escherichia coli (b) Scanning electron
micrograph of E. coli 0157:H7.

.*1

f »■

. ■ ■fj

.im

/ i

"S'.
r*

(a)- '

(b)l

47

1^.12 Salmonella
Salmonella is a genus of rod-shaped, Gram-negative enterobacteria that causes
typhoid fever, paratyphoid fever, and foodborne illness. Salmonella species arc motile
and produce hydrogen sulfide.

Disease-causing Salmonella species have recently

been re-classified into a single species. Salmonella enterica, which has numerous
scrovars. Salmonella Typhi causes typhoid fever. Other salmonellac are frequent
causes of foodborne illness, especially from poultry and raw eggs and more generally
from food that has been cooked or frozen, and not eaten straight away. While these
infections would normally only require a treatment of antibiotics, the long-term usage
of antibiotics in both the poultry and beef industries may have created a strain of
salmonella which is potentially resistant to antibiotics (Tindall ct al 2005, Ryan and
Ray 2004).

Figure 1.13 Electron microscope image of Salmonella.

48

1^,13 Helicobcter
Helicobacter is a genus of Gram-negative bacteria possessing a characteristic helix
shape. They were initially considered to be members of the Campylobacter genus, but
since 1989 they have been grouped in their own genus (Goodwin et al 1989,
Vandamme et al 1991). Some species have been found living in the lining of the
upper gastrointestinal tract, as well as the liver of mammals and some birds. The most
widely known species of the genus is H. pylori. Some strains of this bacterium are
pathogenic to humans as it is strongly associated with peptic ulcers, chronic gastritis,
duodenitis, and stomach cancer. It also serves as the type species of the genus.
Helicobacter spp. are able to thrive in the very acidic mammalian stomach by
producing large quantities of the enzyme urease, which locally raises the pH from ~2
to a more biocompatible range of 6 to 7 (Dunn et al 1997). Bacteria belonging to this
genus are usually susceptible to antibiotics such as penicillin, arc microacrophilic
(require small amounts of oxygen), and arc fast-moving with their flagella (Hua et al
1999).

Figure 1.14 (a) A duodenal ulcer caused by H. pylori, (b) Electron microscope image
of Helicobacter pylori.
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1^.14 Campylobacter
Campylobacter is a genus of Gram-negative bacteria. Motile, with either uni- or bi
polar flagella, the organisms have a somewhat curved, rod-like appearance, and are
oxidase-positive. At least a dozen species of Campylobacter have been implicated in
human disease, with C. jejuni and C. coli the mo.st common. C. fetus is a cause of
spontaneous abortions in cattle and sheep, as well as an opportunistic pathogen in
humans (Sauerwein et al 1993). Infection with a Campylobacter species is one of the
most common causes of human bacterial gastroenteritis (Moore et al 2005) In the
United States, 15 out of every 100,000 people are diagnosed with campylobacteriosis
every year, and with many cases going unreported, up to 0.5% of the general
population may unknowingly harbor Campylobacter in their gut annually. Diarrhea,
cramps, abdominal pain, and fever develop within 2-5 days of pathogenic
Campylobacter infection, and in most people, the illness lasts for 7-10 days. Infection
can sometimes be fatal, and some (less than 1 in 1000 cases) individuals develop
Guillain-Barrc syndrome, in which the nerves that join the spinal cord and brain to the
rest of the body arc damaged, sometimes permanently.

Figure 1.15 Electron microscope image of Campylobacter jejuni.
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1^.15 Candida
Candida is a genus of yeasts. Clinically, the most significant member of the genus is
Candida albicans, which can cause numerous infections (called candidiasis or thrush)
in humans and other animals, especially in immunocompromised patients. Various
Candida species are members of gut flora in animals, including C. albicans. The last
decade has seen the sustained medical importance of opportunistic infections due to
different Candida species, mainly due to the worldwide increase in the number of
immunocompromised patients, who are highly susceptible to opportunistic infections.
Meanwhile, the genome sequence of several Candida species has been completed,
enabling the detailed investigation of some aspects of their biology with the aid of
post-genomic approaches. The basic knowledge gained from these investigations of
pathogenic Candida, and related yeasts, can translate into innovations in the
development of novel antifungal therapies, original approaches for targeted immunointerventions, or highly sensitive diagnosis of fungal infections (Krone et al 2001,
Ryan and Ray 2004).

Figure 1.16 (a) Oral infection of fluconazole resistant Candida Albicans (b) Electron
microscope image of Candida Albicans.

51

12.16 Saccharomyces
Saccliaromyces is a genus in the kingdom of fungi that includes many species of
yeast. Saccliaromyces is from Latin meaning sugar fungus. Many members of this
genus are considered very important in food production.

One example

is

Saccliaromyces cerevisiae, which is used in making wine, bread, and beer. Other
members of this genus include Saccliaromyces hayanus, used in making wine, and
Saccliaromyces boulardii, used in medicine (Ryan and Ray 2004). Many signalling
pathways

of universal

importance

in

eukaryotes

were

first

discovered

in

Saccliaromyces. Retrograde signaling, which consists of signaling pathways leading
from the mitochondria to the nucleus, was first discovered in Saccliaromyces
cerevisiae. To protect itself from acetic acid-mediated programmed cell death,
Saccliaromyces cerevisiae utilizes acid stress adaptation. The response to a
programmed cell death by acetic acid is mediated through ROS-dependent apoptotic
pathways. A study by Giannattasio and co-workers (2005) gave some evidence that
H2O2 detoxification may play a role in preventing yeast cell death in response to
acetic acid (Bammert and Fostcl 2000).

Figure 1.17 Electron microscope image of Saccliaromyces cerevisiae.
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Section 2

Materials & Methods
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2.1 Materials
2.1.1 Bacterial cultures
Table 2.1. Bacterial & Yeasts strains used as target strains in the study.
Genus / Species

Strain Number

Original Source

Growth Medium

Bifidobacterium longum

DSMZ8809

Intestine of infant

MRS-Cysteine

Bifidobacterium adolescentis

DSMZ20083

Intestine of adult

MRS-Cysteine

Bifidobacterium bifidum

DSMZ20456

Stool of breast-fed infant

MRS-Cysteine

Bifidobacterium breve

DSMZ20213

Intestine of infant

MRS-Cysteine

Bifidobacterium lactis/animalis

JCM7117

Animal faeces

MRS-Cysteine

Bifidobacterium infant is CIT026

CIT026

Intestine of infant

MRS-Cysteine

Clostridium aerotolerans

DSMZ5434

Sheep rumen

Reinforced Clostridial Medium

Clostridium colicanis

DSMZ13634

Canine intestine

Reinforced Clostridial Medium

Clostridium lactatifermenians

DSMZ14214

Caecum of broiler chicken

Reinforced Clostridial Medium

Clostridium difficile

ATCC43593

1 luman intestine

Reinforced Clostridial Medium

Clostridium caproicum.

DSMZ 11322

Institute Pasteur

Reinforced Clostridial Medium

Bacteroides vulgatus

DSMZ 1447

Human faeces, type strain

Reinforced Clostridial Medium

Bacteriodes acidifaceins

DSMZ 15896

Caecum of mouse

Reinforced Clostridial Medium

Enterococcus faecalis

DSMZ6134

Human intestine

Brain and Heart Infusion

Enterococcus faecalis

DSMZ20380

Abscess

Brain and Heart Infusion

Enterococcus faecalis

DSMZ20478

Human intestine

Brain and Heart Infusion

Enteroccus faecium

DSMZ20477

Serogroup D. Type strain.

Brain and Heart Infusion

Enterococcus faecium

DSMZ13589

Human faeces

Brain and Heart Infusion

Lactobacillus acidophilus

DSMZ20079

Scav. Human

MRS Medium

Lactobacillus alimentarius

DSMZ20249

Marinated fish product

MRS Medium

Lactobacillus casei

DSMZ20011

Cheese

MRS Medium

DSMZ20()81

Yoghurt. Serogroup E

MRS Medium

DSMZ6629

Intestine of rat.

MRS Medium

Lactobacillus Johnsonii

DSMZ10533

Human blood

MRS Medium

Lactobacillus plantarum

DSMZ20174

Pickled cabbage.

MRS Medium

Lactobacillus reuteri

DSMZ20016

Intestine of adult

MRS Medium

Lactobacillus sakei

DSMZ20100

Stool of breast-fed infant

MRS Medium

Lactobacillus delbrueckii ssp.
bulgaricus
Lactobacillus intestinalis
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Lactobacillus vaginalis

DSMZ5837

Vaginal swab

MRS Medium

Lactococcus lactis ssp. cremoris

DSMZ20069

r-'rom cheese

M17 Medium

Lactococcus lactis ssp. cremoris

MG 1363

From cheese

GM17 Medium

Lactococcus lactis ssp. lactis

DSMZ20729

From cheese

M17 Medium

Streptococcus alactolyticus

DSMZ5199

Colon of pig

Brain and Fleart Infusion

Streptococcus entericus

DSMZ14446

Intestine of cow

Brain and Heart Infusion

Streptococcus infantis

DSMZ12492

Human tooth surface

Brain and Heart Infusion

Streptococcus thermophilus

DSMZ20617

Bovine milk

Brain and Heart Infusion

Eschericha coli

DSMZ787

Human intestinal pathogen

Brain and Heart Infusion

Eschericha coli

DSMZ1058

Human intestine

Brain and Heart Infusion

Human MRSA (CUH)

Brain and Heart Infusion

Human MRSA (CUH)

Brain and Heart Infusion

1 luman skin, nose

Brain and Fleart Infusion

Human MRSA (CUH)

Brain and Heart Infusion

Bovine Mastitis Isolate

Brain and Heart Infusion

Human MRSA (CUH)

Brain and Heart Infusion

Human MRSA (CUH)

Brain and Heart Infusion

Soil

Brain and Heart Infusion

1 luman isolate (CUH)

Brain and Heart Infusion

Poultry

Brain and Heart Infusion

1 luman isolate (CUl 1)

Brain and Heart Infusion

1 luman isolate (CUl 1)

Brain and Heart Infusion -Blood

1 luman isolate (CUl 1)

Brain and Heart Infusion-Blood

Infant formulas

Brain and Heart Infusion

1 luman isolate

Sabouraud medium

Human isolate (CUH)

Sabouraud medium

Human isolate (CUH)

Sabouraud medium

Skins of fruit

Sabouraud medium

Staphylococcus aureus
Staphylococcus aureus
Staphylococcus aureus
Staphylococcus aureus
Staphylococcus aureus
Staphylococcus aureus
Staphylococcus aureus
Bacillus subtilis
Salmonella enterica

M249318
M250594
A'1CC25923
M251760
DPC5246
M2310()3
M253472
ArCC6633
Newport

146

Salmonella enterica

Virchow 104

Salmonella enterica

GUI 161(04)

Helicobcter pylori

MS2583

1 lelicobcter pylori

MS4141
DSMZ4485

Enterobacter sakazakii
Candida albicans

DSMZ 1386

Candida albicans

MS21286

Candida albicans
Saccharomyces cerevisial

MS21292
DSMZ1333

Enterobacter spp.

DSMZ4485

Human isolate (CUH)

Brain and Heart Infusion

Listeria monocytogenes

L028

Human isolate (CUH)

Brain and Heart Infusion

Campylobacter spp.

DSMZ4688

Human isolate (CUH)

Brain and Heart Infusion

Mycobacterium avium spp.

MC2155

Human isolate (CUH)

Brain and Heart Infusion
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2,1.2 Lactic Acid Bacterial producer
Table 2.2. Lactic acid Bacteria (LAB) strains producing low molecular mass
antimicrobial compounds.
Strain
Number

Original
Source

Growth
Medium

Antimicrobials
produced

Lactobacillus
pi ant arum

FST1.7 (FST)

ucc

MRS

Lactobacillus
plantarum

FST1.9
(TMW)

ucc

MRS

Lactobacillus
amylovorus
Weissella cibaria

FST 1.1 a (LA)

ucc

MRS

Phenyllactic acid
Cyclic dipeptide; Cyclo [LLeu-L-Pro]
Cyclic dipeptide: Cyclo [LPhe-L-Pro]
Phenyllactic acid
Cyclic dipeptide; Cyclo [LPhe-L-Pro]
Antifungal activity

FST1.31
(WC)
DSMZ1359

ucc

MRS

Antifungal activity

DSMZ

MRS

No antifungal activity
(negative control)

Genus and Species

Lactobacillus
amylovorus

2.1.3 Bacterial culture media
2.1.3.1 MRS-Cysteine medium
Prepared by dissolving 52g MRS (Oxoid) in IL of distilled water. Cysteine 0.5g was
added (Sigma). Distribute into final containers and sterilize by autoclaving at 121°C for
15 minutes.

2.1.3.2 Reinforced Clostridial Medium (RCM)
Prepared by dissolving 38g RCM (Oxoid) in IL of distilled water. Distribute into final
containers and sterilize by autoclaving at 121°C for 15 minutes.
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2.13.3 Brain and Heart Infusion (BHI)
Prepared by dissolving 37g BHI (Oxoid) in IL of distilled water. Distribute into final
containers and sterilize by autoclaving at 121°C for 15 minutes.

2.1.3.4MRS Medium
Prepared by dissolving 52g MRS (Oxoid) in IL of distilled water. Distribute into final
containers and sterilize by autoclaving at 121°C for 15 minutes.

2.1.3.5M17 Medium
Prepared by dissolving 37.25g Ml 7 (Oxoid) in 950 mL of distilled water. Distribute into
final containers and sterilize by autoclaving at 121 °C for 15 minutes.

2.1.3.6 GM17 Medium
Prepared by dissolving 37.25g M17 (Oxoid) in 950 mL of distilled water. Add 0.5%
Glucose (Analar, UK). Distribute into final containers and sterilize by autoclaving at
121°C for 15 minutes.
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2.1.3.7 Helicobacter Brain and Heart Infusion with Blood
Prepared by dissolving 37g BHI (Oxoid) in IL of distilled water. Distribute into final
containers and sterilize by autoclaving at 121°C for 15 minutes. Added 10% of de-

fibrinated horse blood was added after cooling to 45°C. (Biological Laboratories)

2.1.3.8 Sabouraud medium
Prepared by dissolving 65g Sabouraud (Difco) in 1 L of distilled water. Distribute into
final containers and sterilize by autoclaving at 121°C for 15 minutes.

2.1.3.9 MRS4 Medium

Prepared by dissolving 10 g of tryptone (Oxoid), 5 g of meat extract (Oxoid), 5 g of yeast
extract (Oxoid), 5 g of C2H3Na02 x Sf^O, 3 g of ammonium chloride, 2.6 g of K2HPO4 x
3H2O, 4.0 g of KH2PO4, 0.1 g of MgS04.7H20, 0.05 g of MnS04 x- 4H2O, 0.5 g of
cysteine-HCl (Sigma), 1 ml of Tween 80 (Sigma) in 1 L of distilled water. Adjust pH to
5.8. Distribute into final container and sterlize by autoclaving at 121°C for 15 min.
Sugars were added separately from individual stock solutions to the following final
concentrations: Maltose: 1%, fructose: 0.5%, glucose: 0.5%. One ml of vitamin stock is
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added. This was composed of 0.2 g/liter of the following vitamins: cobalamin, folic acid,
nicotinic acid amide, pantothenic acid, pyridoxal phosphate, and thiamine. The vitamin
mix was sterilized by filtration prior to addition to the autoclaved MRS. When required
as an acid/base indicator 0.05g/l of Bromcresol green was added.

2.1.4 1% LactiSAL Solution (pH 1,0 ~ pH 9.0)
Phosphate buffer was adjusted to a range of pH values (from 1.0, 2.0. 3.0, 4.0, 5.0, 6.0,
7.0, 8.0 and 9.0). 1% of LactiSAL was added, allowed to dissolve and left for 2 hours
before use.

2.1.5 Lactate Dehydrogenase Assay
2.1.5.1 Tris Maleate Buffer pH 7.0
A: 0.2 M T'ris acid maleate (24.2g Tris + 23.2g maleic acid in 1000ml)
B:0.2MNaOH (0.8g/100ml)

2.1.5.2 NADH
MW = 709.4= IM
4.5mM = 3.1923g/l = 0.0319g/10ml
N.B. NADH should be covered with tin foil. It lasts one week when stored at 4°C.
Monitor the initial levels of absorbance, they should remain the same, if they drop,
replace the NADH.
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2.1.5.3 30 mM Fructose BisPhosphate (FBP)
MW = 550.18 = IM
30 mM = 16.5054g/l = 0.1651g/10ml
(lasts one week when stored at 4°C).

2.1.5.4 300 mM Sodium PyruvateFBP
MW= 110.04= IM
30 mM = 33.012g/l = 0.33012g/10ml
(lasts one week when stored at 4°C).

2.1.6 .Effect of LactiSAL on microbial inhabitants of porcine
intestine.
2.1.6.1 Isolation of fresh porcine gastrointestinal tract material
containing typical viable bacteria
A 24--week old pig of weight 97 kg was slaughtered and its gastrointestinal tract (GIT)
removed. Samples were removed from the GIT at four sites, namely the stomach, the
jejunum, the terminal ileum, and the descending colon. The pH of the material at each
location was as follows: stomach pH 5.25; jejunum pH 6.27; terminal ileum pH 6.34 and
descending colon pH 6.18 (the high stomach pH was due to the animal fasting prior to
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slaughter). Samples were kept on ice and used within 24 hours of slaughter so that there
was minimal die-off of GIT microbial inhabitants.

Colon

Stomach

2.1.6.2 API rapid ID 32A & API 50 CHL

Species identification of Clostridium & Lactobacillus & Bifidobacteria (BioMerieux,
Mary T Etoile, France.).

2.1.7 Cell toxicity studies (Cell culture test)

2.1.7.1 BHK Cells
BHK cells (Baby Hamster Kidney) are fibroblast cells which are anchorage-dependent,
ie. they grow in a monolayer, on the bottom of a suitable tissue culture vessel.
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2.1.7.2 BHK Cell Medium
GMEM (Glasgow's Minimal Essential Medium)
NCS (Newborn Calf Serum)
TPB (Tryptone Phosphate Broth)
Glut./P/S (Glutamine-Penicillin-Streptomycin Solution)
10ml of NCS is added to a sterile “Duran” bottle.
Add 10ml TPB.
Add 1ml Glut P/S solution.
Add GEM to a final volume of 100ml.
This is labelled and store at 4^C. Medium is sterility tested prior to use.

2.2 Methods
2.2.1 Determination of MICs of ImmunoSAL against target
bacteria.
Different volumes ImmunoSAL (powder form of LactiSAL) solution were added to the
agar (Tablet and Table2) and mixed well before pouring the plates. Bacteria were
streaked out on these plates (complex streak). Incubated under conditions appropriate to
the microorganism being tested. Recorded clear zone of inhibition by different
concentrations of ImmunoSAL.
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2.2.2Late log-phase broth cultures of targets and effect of
different concentrations of inhibitor
2.2.2.1 Grew a fresh culture up overnight by inoculating (1%) into 10ml of appropriate
broth medium.

2.2.2.2 Inoculated 1ml fresh overnight culture of target microorganism into 99ml of
broth (total 100ml) in a flask. Grow at appropriate temperature in waterbath. Aseptically
removed 1-ml samples every 30 minutes for spectrophotometer readings at 600nm. Used
1 ml of the same (uninoculated) broth as a blank for the spectrophotometer.

2.2.2.3 Continue to grow target culture and target culture-plus-inhibitor (multiple
copies, each with a different concentration of inhibitor). Removed 1 ml for plate counts at
the time of addition of inhibitor and also after the spectrophotometer readings indicate
that the control culture has reached the stationary phase of growth.

2.2.3.Effect of pH on LactiSAL activity.

2.2.3.1 plate assay
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Lactobacillus johnsonii DSMZ10533 was used as a sample bacterium. Phosphate buffer
was adjusted to a range of pH values (from 1.0, 2.0. 3.0, 4.0, 5.0, 6.0, 7.0, 8.0 and 9.0).
LactiSAL was made up in each of these phosphate buffers and left at the pH of the buffer
for 2 hours. Then the different pH-treated LactiSAL batches were added to MRS agar to
final concentrations of 0.133%, 0.2%, 0.33% and 1.0%. This are the concentrations of
LactiSAL which were shown to be inhibitory to Lactobacillus johnsonii DSMZ10533.
Colony sizes were then evaluated. Colony sizes indicate the level of inactivation of the
r.actiSAL by pH treatment.

2.2.3.2 Late log-phase broth cultures of Lb. johnsonii DSMZ10533 and
effect of 1% LactiSAL (pH 1.0 to pH 9.0 )

2.2.3.2.1 Grew a fresh culture up overnight by inoculating (1%) into 10ml of
appropriate broth medium.

2.2.3.2.2 Inoculated 1ml fresh overnight culture of target microorganism into 99ml of
broth (total 100ml) in a flask. Grow at appropriate temperature in waterbath. Aseptically
removed 1-ml samples every 30 minutes for spectrophotometer readings at 600nm.
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2.2.3.2.3 Continued to grow target eulture and target culture-plus-inhibitor (multiple
copies, each with a different concentration of inhibitor/ each at a different pH). Removed
1 ml for plate counts at the time of addition of inhibitor and also after the
spectrophotometer readings indicate that the control culture has reached the stationary
phase of growth as before. Titres of bacteria on plate counts from the different pH
treatments indicated the level of inactivation of the LactiSAL by pH treatment.

2.2.4. Duration of exposure to LactiSAL concentrate.

LactiSAL was added to an actively growing cultures (various genera). With each culture,
LactiSAL was added at an inhibitory concentration and allowed to act for 5 minutes and
30 minutes. After 5 minutes, 1 ml of culture was removed and diluted decimally in
quarter-strength Ringers solution and plated out on the appropriate agar medium. The
dilution process has the effect of immediately removing exposure to LactiSAL. A 1 ml
aliquot was also removed after 30 minutes and again diluted and plated out. Plate counts
at both time-points indicated the degree of LactiSAL activity after 5 minutes and after 30
minutes.
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2.2.5. Lactate Dehydrogenase Assay

Total LDH was assayed using the method of Cogan et al (1981) in the presence of
Fructose 1,6 bisphosphate. The spectrophotometer was set at 340nm.

2.2.5.1 To 2.7 ml of Tris Maleate buffer pH 7.0 added 0.1ml of NADH (4.5 mM ),
0.1ml of FBP (30 mM) and 0.1 of sample diluted appropriately in a 3 ml cuvette.

2.2.5.2 Place cuvette was placed in spectrophotometer.

2.2.5.3 0.1 of Sodium Pyruvate (300mM) was added, stirred thoroughly.

2.2.5.4 Timer was set for 3 minutes.

2.2.5.5 Recorded readings at 0, 1,2 and 3 minutes. Activity was expressed as unit per
ml of extract, where one unit was defined as the amount of enzyme that catalyses the
oxidation of 1 um NADH per minute. The readings were compared to those of a control
bacterium which is not susceptible to leakage.
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2.2.6. Effect of LactiSAL on microbial inhabitants of porcine
intestine.

2.2.6.1 LactiSAL (1ml) was added to final concentrations of 0.1% and 0.4% to 9 ml
samples of GIT material in test-tubes and mixed using a vortex mixer. In negative
controls, 1 ml water was added instead of lactiSAL solution. The colon sample, being
semi-solid, was diluted 5-fold in quarter-strength Ringer solution before the addition of
LactiSAL. After exposure to LactiSAL, 1ml was withdrawn from samples, sequentially
diluted 10-fold and spread-plated on different agar media to facilitate enumeration of (a)
total culturable bactera: brain and heart infusion agar; (b) bifidobacteria: MRS-cysteinemupirocin; (c) lactobacilli: MRS; (d) clostridia: reinforced clostridial medium. Plates
were incubated anaerobically for at least 48 h after which colonies were enumerated.

2.2.6.2 API 50 CHL
Table 2.3 The biochemical tests and composition of API 50 CH strip is indicated
overleaf
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Tube
0
1
2
3

Test

Active ingredients

Active ingredients

GLY
ERY
DARA

Tube
25
26
27
28

Test

Control
Glycerol
Erythritol
D-arabinose

ESC
SAL
CEL
MAL

4
5

LARA
RIB

L-arabinose
D-ribose

29
30

LAC
MEL

6
7
8

DXYL
LXYL
ADO

31
32
33

SAC
TRE
INU

9
10
11
12
13
14
15
16
17
18
19

MDX
GAL
GLU
FRU
MNE
SBE
RHA
DUE
INO
MAN
SOR

34
35
36
37
38
39
40
41
42
43
44

MLZ
RAF
AMD
GLYG
XLT
GEN
TUR
LYX
TAG
DFUC
LFUC

D-melezitose
D-rafmose
Amidon(starch)
Glycogen
Xylitol
Gentiobiose
D-turanose
D-lyxose
D-tagatose
D-fucose
L-fucose

20

MDM

45

DARL

D-arabitol

21
22

MDG
NAG

D-xylose
L-xylose
D-adonitol
Methyl-PD xylopyranoside
D-galactose
D-gulcose
D-fructose
D-mannose
L-sorbose
L-rhamnose
Dulcitol
Inositol
D-mannitol
D-sorbitol
Methyl-aD mannopyranoside
Methyl-aD glucopyranoside
N-acetylglucosamine

Esculin ferric citrate
Salicin
D-celiobiose
D-maltose
D-lactose
(bovine origin)
D-melibiose
Dsaccharose(sucrose)
D-trehalose
Inulin

46
47

LARL
GNT

23

AMY

Amygdalin

48

2KG

24

ARB

Arbutin

49

5KG

L-arabitol
Potassium glueonate
Potassium 2Ketoglueonate
Potassium 5Ketogluconate
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1,2,1 Cell toxicity studies

1,2.1.\ Cytotoxicity test using BHI-Blood agar.
I'he complex streak plate method was used. Producer strains were streaked out. Clearing
of blood agar around colonies indicated haemolysis.

2,2.7.2 Tissue culture cytotoxicity test

2.2.7.2.1 Recovery of Cells

Wearing suitable protective gloves and mask, a vial of frozen BHK cells was removed
from the freezer and plunged directly into a warm water bath (37 °C). Contents were
agitated gently until the cell suspension had thawed completely. Vial was wiped with
70% ethanol, then the contents were aseptically transferred (using a 1 ml plastic pipette)
'y

into a 25 cm flask containing 5ml of sterile BHK medium. The cells were incubated at
37 °C for 2 days until confluent growth was observed. Cells were checked after 24h and
48h hours post-seeding to ensure that they had recovered and were growing.
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12.1.22 Passing BHK Cells

The medium from the 25cc flask was transferred into a clean container. The monolayer
was rinsed twice with Phosphate Buffered Saline. Three ml of lx trypsin (Gibco, UK)
was added and the flask was rocked gently to spread the trypsin evenly over the
monolayer. This detached the monolayer. As soon as the monolayer had detached, 5ml of
medium was added to the flask, mixed gently to break up clumps. Cells and medium
were added to a sterile 50ml Falcon tube and centrifuged at l,800g for 5mins to pellet the
cells, thus separating them from the trypsin, fhe supernatant was removed, and 10 ml of
fresh BHK medium was added. I'he tube was gently agitated to resuspend the pellet until
a homogeneous suspension was obtained. The contents were transferred to a 25-ml llask
which was incubated at 37

for 24 hours.

2.2.7.2.3 Effect of low mass molecular antimicrobial compounds on BHK cells

The medium was poured from the flask into a clean container. The monolayer was rinsed
twice times with PBS. The BHK medium contain different concentration of antimicrobial
compounds was added, rocked the flask gently to spread evenly over the monolayer, 1ml
of PBS was added to one flask as control. All flasks were incubated at 2)1

for 1 hour.

The liquid was removed and 15ml of medium was added to each of the flasks. All flasks
were incubated at 37for 2 days. Checked all the flasks under microscope after .
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2.2.8 The overlay method

The overlay method was performed using buffered MRS4 agar plates on which LAB are
inoculated as 3 spots and incubated at 30

for 48h in anaerobic jars. There after, overlay

with 1 ml of malt extract soft agar (2% malt extract, 0.7% agar; Oxid) contaning 1%
target bacteria . Incubated the plates aerobically at 30*^0 for 48h. Examined the plates for
clear zones of inhibition around.

2.2.9 The microtitcr plate well assay

fo each well added 0.1ml of different cone, inhibitor and 0.1 ml of suitable medium
contain 1% of target bacteria. Used microtiter plate reader got reading of targets’s growth.

2.2.10 The disc diffusion assay

The antimicrobial compounds were applied to an agar plate on a paper disc. E. coli PI432
was used as a target bacterium, 0.1ml of fully growth culture spread on BHI agar plates.
Inhibition discs containing 15.25mg/ml of Phenyllactic acid were added on the plates.
Spread plates of E.coli had discs containing 15.25mg/ml lactic acid were used as control.
Plates were incubated at 37 °C for 24h. Recorded the size of clear zone of inhibition.

71

Section 3

Results Part 1
Antimicrobial properties of the lipoprotein LactiSAL

Section 3 (Part I) of the results was carried out on a confidential
basis for an Enterprise Ireland-funded industry.
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3.1. Observations with LactiSAL concentrate.
The bacteria in Table 2.1 (Materials and Methods section) were plated on their
respective agar media containing different concentrations of LactiSAL. Each culture
was triple streaked for clear isolated colonies. Diameters of colonies were measured in
mm and the results of each of the platings arc presented in Tables 3.1 - 3.13.
Subsequently, the growth rates of the strains were recorded. Then, within each genus,
one strain was selected for challenge during a growth cycle in liquid medium, using
different concentrations of LactiSAL. The observations with the different genera arc
presented on the following pages.

3>1.1 Lactobacillus
Table 3.1 Effect of iMctiSAL concentration on colony size of Lactobacillus species on
MRS agar medium
Colony Diameter (mm)

Species

Lh. acidophilus
DSM7.20079
Lh. alimentarius
l)SMZ20249
Lh. casei
DSM720011
Lh. dcihriieckii
s.s'p. hulgaricus
DSMZ20081
Lh. intestinalis
DSM76629
Lh. jolmsonii
DSM710533
Lh. planlariim
DSM720174
Lh. reuteri
DSMZ20016
Lh. sakei
DSMZ20100
Lh. vaginalis
DSMZ5H37

0.4 %
1 iiCtiSAJ.
(1:250)

0.33 %
DictiSAI
(1:300)

0.2 %
I^ctiSAI
(1:500)

0.133 %
liictiSAL
(1:750)

0.1 %
IMctiSAL
(1:1000)

0.067 %
liictiSAL
(1:1500)

0%
l>actiSAI.
(control)

0

0

0.2

0.2

0.5

0.5

1.0

0

0

0

0

0.2

0.5-0.8

1.0

0

0

0.2

0.2

0.5

0.5-1.0

2.0

0

0

0

0

0

0

1.5-2.0

0

0

0

0.5

1.5-2.0

1.5 - 2.0

1.5-2.0

0

0

0

0.2

1.0-1.5

1.0-1.5

1.0- 1.5

0

0

0

0

1.5

1.5

1.5 - 2.0

0

0

0.2

0.5

2.0

2.0

2.0 - 2.5

0

0

0

0

0

0

1.0

0

0

0

0

0.5

1.0

1.0

LactiSAL concentrations of 0.33% and greater arc completely inhibitory to all the
above lactocacilli. Growth of Lactobacillus occurs at 0.2% LactiSAL maximum.
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Figure 3.1. Comparison of growth rates of the different species of Lactobacillus in
MRS broth.

123456789 1011 12 1314 1516171819
Time (hours)
Lb. vajiinalis
^ Lb. intcstinalis
— Lb. rcutcri
1^1111411.7

Lb. buljiaricus
Lb. casci
Lb. alimcntarius —Lb. johnsonii
1^1/.

l.UljjC

Lactobacillus johnsonii was chosen as a typical human isolate with relatively rapid
growth properties by compari.son with some other isolates available. This isolate was
selected for challenge with LactiSAL during growth in liquid medium. Other species
oi Lactobacillus johnsonii (eg patented strain NCC533) are classed as members of the
acidophilus group of intestinal lactobacilli which has been extensively studied for their
"probiotic" activities that include pathogen inhibition, epithelial cell attachment, and
immunomodulation.
f.b johnsonii was challenged with LactiSAL at concentrations indicated in Table 3.1.
The behaviour of this representative Lactobacillus at 0%, 0.07%, 0.10%, 0.20% and
0.40%; LactiSAL is shown in Figure 3.2.
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Figures.!. Growth of Laclohacillus johnsonii in the presence of inhibitory and
suh-inhihitory concentrations of LactiSAL. The bacterial count immediately before
addition of LactiSAL is shown. Counts after exposure to different concentrations of
LactiSAL for several hours are presented on the right. These latter counts were taken
when the stationary phase of growth was reached in the LactiSAL-free control.

0% Lactisal

0.67% Lactisal -^0.1% Lactisal

0.2% Lactisal

0.4% Lactisal

The data in Figure 3.2 indicates that LactiSAL inhibits growth, brings about a
reduction in cell numbers at 0.2%, and causes a significant drop in cell numbers at
0.4% where the titre was reduced from 4.6 x 10^ to 4.0 x 10\ The drop in optical
density observed where 0.4% LactiSAL was included indicates that cell lysis is
occurring at this level.
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3.12 Bifidobacterium

Bifidobacteria, which have a record of being difficult to cultivate, grow relatively well
on MRS which is supplemented with 0.5% cysteine (the antibiotic mupirocin can be
incorporated as a selective agent).

Table 3.2 Effect of LactiSAL concentration on colony size of Bifidobacterium species
on MRS-Cysteine medium
Colony Diameter (mm)

Species
0.2 %
I>actiSAL
(1:500)

0.133 %
IxicliSAL
(1:7.50)

0.1 %
l^actiSAl
(1:1000)

0.067 %
l.acliSAL
(1:1.500)

0.033 %
l^ctiSAL
(1:3000)

0.01 %
1 acliSAI,
(1:10,000)

0%
l^actiSAI
(control)

0

0,2

0.5

1.0

1.5

2.0

2.0

0

0

0.5

0.8

1.0

1.5

1.5

0

0

0.2

0.2

0.5

1.2

1.2

0

0.2

1.0

1.0

1.5

2.0

2.0

B. lactisJCMJll?

0

0

0.2

0.2

0.5

1.0

1.0

B infaniis ('IT026

0

0.2

0.5

1.0

1.5

2.0

2.0

B. loni'um
DSM'hoOBH
B. adolescent is
I)SMZ2()()B3
B. hifuliim
DSMZ20456
B. breve
DSMZ2()213

LactiSAL concentrations of 0.2%; and greater are completely inhibitory to all the
above Bifidobacterium. Growth of Bifidobacterium occurs at 0.133%; maximum.
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Figure 3.3. Comparison of growth rates of the different species of Bifidobacterium in
MRS-Cysteine broth.

Time (hours)

B. longum DSMZ2(X)88
B. bifidum DSMZ2()456
-^B. lactis JCM7117

B. infantLs CIT()26
B. breve DSMZ2()213

The Bifidobacterium species were evaluated for ability to grow in MRS-cysteine.
Bifidobacterium bifidum was selected, as it showed the fastest growth by comparison
with the other five species (data not shown). This strain was then challenged with
LactiSAL at a range of concentrations which inhibited growth and which allowed
colony formation to occur, namely 0.2%, 0.133% and 0.1%. The results are shown in
Figure 3.4 .
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Figure 3.4. Growth of Bifidohacterium hifidum DSMZ2()456 in the presence of
inhibitory and suh-inhihitory concentrations of LactiSAL. The bacterial count
immediately before addition of LactiSAL is shown. Counts after exposure to different
concentrations of LactiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL -free con trol.

-{)% lactiSAL

0.001% lactiSAL

—A-

^ 0.067% lactiSAL

-0.1% lactiSAL
—h--0.2% lactiSAL

-^0.133% lactiSAL

-0.033% lactiSAL

The data in Figure 3.4 indicates that LactiSAL inhibits growth, brings about a
reduction in cell numbers at 0.033%, and causes a significant drop in cell numbers at
0.2%, where the titre was reduced from 9.2 x 10^ to 2.8 x 10'^. The drop in optical
density observed where 0.2%^ LactiSAL was included indicates that cell lysis is
occurring at this level.
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3.U Enterococcus

A number of enterococci arc recognised as having a probiotic effect in humans and
animals. These belong to the species fecium and fecalis. These strains were grown in
BHI medium.

Table 3.3 b^ffect of LactiSAI. concentration on colony size of Enterococcus species on
lh ain and Heart Infusion medium
Species

Knt. jaecalis
nSMZ6LU
Ent. face ell is
DSMZKmo
Em. faecalis
l)SMZ2()47S
Em. faecium
I)SMZ135S9

Colony Diameter (mm)
0.4 %
liictiSA
1
(1:250)

0.33 %
I.actiSA
I.
(1:300)

0.2 %
I cell’s A
I
(1:500)

0.133 %
l>actiSAF
(1:750)

0.1 %
I^ctiSAF
(1:1000)

0.067 %
I>actiSAI.
(1:1500)

0.033 %
liictiSAL
(1:3000)

0%
I.acliSAI.
(control)

0

0

0.5

1.0

1.5

2.0

2.5

3.0

0

0.2

0.5

0.8

1.0

1.5

2.0

3.0

0

0

0.5

1.0

1.5

2.0

2.5

4.0

0

0

0.2

0.5

0.5

1.0

1.5

2.5

LactiSAL concentrations of 0.4% and greater arc completely inhibitory to ail the
above Enterococcus. Growth of Enterococcus occurs at 0.33%; maximum. As with the
lactobacilli and bifidobacteria, the growth characteristics of the enterococci were
compared. Growth characteristics in BHI broth were broadly similar in all five
isolates (data not shown, but see negative control in Figure 3.5).
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Figure3.5. Comparison of growth rates of the different species of Enterococcus in
HHl broth.

The human intestinal isolate Enterococcus faecium DSMZ13589 was chosen for the
purpose of the LactiSAL challenge. The response of this culture to LactiSAL at 0%,
0.07%, 0.1%, 0.133%, 0.2% and 0.4% LactiSAL is shown in Figure 3.6.
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Figure 3.6 Growth of Enterococcus faecium DSMZJ3589 in the presence of
inhibitory and sub-inhibitory concentrations of LactiSAL. The bacterial count
immediately before addition of IMctiSAL is shown. Counts after exposure to different
concentrations of LactiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL -free control.

1.2
1
0.8
0.6
0.4

0.2
0

Time (hours)
■^0% lactiSAL
■^0.1% lactiSAL

^ 0.07% lactiSAL
0.133% lactiSAL

^0.2% lactiSAL

■^0.4% lactiSAL

The data in Figure 3.6 indicates that LactiSAL inhibits growth, brings about a
reduction in cell numbers at 0.4%, and causes a significant drop in cell numbers at
0.4% where the titre was reduced from 2.0 x Uf to 4.2 x l(/\ The drop in optical
density observed where 0.4% LactiSAL was included indicates that cell lysis is
occurring at this level.
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3.1.4 Streptococcus
Table 3.4 Effect of LactiSAL concentration on colony size of Streptococcus species on
BHI medium.

Species

Strep, alactolyticus
DSMZ5199
Strep, entericas
DSMZ14446
Strep, infantis
DSMZ12492
Strep, thermophilus
DSMZ2()617

Colony Diameter (mm)
0.66 %
liictiSAI.
(1:LS0)

%

fiictiSAI.
(1:200)

0.4 %
I.actiSAL
(1:250)

0.2 %
I^ctiSAl^
(1:500)

0.1 %
I>actiSAI.
(1:1000)

0.066 %
I^ctiSAI.
(1:1500)

0%
I^ctiSAI.
(control)

0

0

0

0

0.2

0.4

1.0

0

0

0

0

0

0

2.5

-

3.0

0

0

0

0.2

0.8

1.5-2.0

2.5

-

3.0

0

0

0

0.2

1.0

1.5

0.5

2.0 - 2.5

Concentrations of LactiSAL greater than 0.2% LactiSAL were inhibitory. The four
species were then examined for their growth patterns (see Figure 3.7).
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Figure 3.7. Comparison of growth rates of the different species of Streptococci in BHI
broth.

^ S. thermophilus
S. alactolyticus

S. infantis
^ S. entericus

Streptococcus infantis DSMZ12492, a human isolate with good growth properties in
BHI was selected for further study.
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Figure 3.8 Growth of Streptococcus infantis DSMZJ2492 in the presence of
inhibitory and sub-inhibitory concentrations of LactiSAL. The bacterial count
immediately before addition of LactiSAL is shown. Counts after exposure to diff erent
concentrations of LactiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL-free control.

1.2
1

S 0.8

e
o

O 0.6
Q

n /I

O 0-^
0.2

0

Time (hours)

^0% lactiSAL
0.2% lactiSAL

0.07% lactiSAL -^0.1% lactiSAL
0.4% lactiSAL

In the case of Streptococcus infantis DSMZ12492, concentrations of LactiSAL of
0.1% or greater bring about lysis of bacterial cells as evidenced by the reduction in
optical density and the concomitant reduction in viable cell numbers as ascertained by
plate count.
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3.1.5 Lactococcus

Table 3,5 Effect of LactiSAL concentration on colony size of Lactococcus species on
M17 medium.

Species

I.. lactis ssp.
cremoris
i)SMZ2(K)69
L .lactis ssp.
cremoris MG 1363
I., lactis ssp. lactis
DSMZ2()729

Colony Diameter (mm)
0.2 %
l^ctiSAL
(1:500)

0.133 %
I.actiSAL
(1:750)

0.1 %
I^ctiSAL
(1:1000)

0.067 %
liictiSAl
(1:1500)

0.033 %
I.actiSAl
(1:3000)

0.01 %
I.actiSAI
(1:100(X))

0%
l^ctiSAL
(control)

0

0

0

0.5

1.5

2.5

2.5

()

0

0

0.2

1.5

2.0

2.0

0

(1

0

0.2

1.5

2.0

2.0

Lactococcus is apparently more sensitive to LactiSAL than the phylogcnetically
similar Gram-positive streptococci and enterococci. LactiSAL concentrations of 0.1%
and greater arc completely inhibitory to all the above Lactococcus strains. Growth of
Lactococcus occurs at 0.067% LactiSAL maximum.
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Figure 3.9. Comparison of growth rates of the different species of Lactococcus in
GM17 broth.

10

11

Time(hours)
L. lactis ssp. cremoris DSMZ2()()69
L .lactis ssp. cremoris MG 1363
L. lactis ssp. lactis DSMZ2()729

The growth patterns of the above three strains were similar (see negative control in
Figure 3.9). Therefore, L. lactis ssp. cremoris MG 1363 was selected for further study
where 0%, 0.01%, 0.033%, 0.067% , 0.1% LactiSAL was added to an early-log
culture.
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Figure 3.10 Ci rowth of L .lactis ssp. cremoris MG1363 in the presence of inhibitory
and suh-inhihitory concentrations of LactiSAL. The bacterial count immediately
before addition of LactiSAL is shown. Counts after exposure to different
concentrations of LactiSAI. for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL-free control.

1.2
1
0.8
0.6

0.4
0.2

0

3

4

5

6

Time (hours)
■^0% lactiSAL
-^0.033% lactiSAL
^0.1% lactiSAL

{).()1% lactiSAL
0.067% lactiSAL

Lactococcus lactis is confirmed to be highly sensitive to LactiSAL. Cell lysis is
evident as with previous Gram-positive bacteria, from the decrease in OD and the
decrease in cell number when inhibitory concentrations of LactiSAL arc present (e.g.
0.1% LactiSAL plot in Figure 3.10 above).
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3.1.6 Escherichia coli

The Gram-negative bacterium has been included for comparison reasons. Both E.coli
strains were evaluated at different levels of LactiSAL during growth in liquid
medium.

Table3.6 Effect of LactiSAL concentration on colony size of Escherichia coli species
on Brain and Heart Infusion medium.

Species

I'ischcricha aili
I)SMZ787
h'schcricha a)li
DSMZ1058

Colony Diameter (mm)
3.0 %
l.acliSAL
(l:33)

2.0 %
I.actiSAI.
(l:50)

1.0%
I^ctiSAL
(1:100)

0.67 %
I^ctiSAI,
(1:150)

0.33 %
I iictiSAI
(1:300)

0.1 %
I^ctiSAI
(1:1000)

0%
I.actiSAI.
(control)

0.5

0.5

2.0

2.5

3.0

3.0

3.0

0

0.2

1.5

2.5

3.0

3.0

3.0

LactiSAL concentrations of 3.0% greater are completely inhibitory to all the above
Escherichia coli. Thus, this bacterium is significantly more tolerant to LactiSAL than
all the Gram-positive bacteria described earlier.
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Figure 3.11 Growth of K. coli I)SMZ1()58 in the presence of inhibitory and
sub-inhibitory concentrations of LactiSAL. The bacterial count immediately before
addition of LactiSAI. is shown. Counts after exposure to different concentrations of
LactiSAL for several hours are presented on the right. These latter counts were taken
when the stationary phase of growth was reached in the LactiSAL-free control.
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Figure 3.12 G rowth ofE. coli DSMZ7S7 in the presence of inhibitory and
snh-inhibitory concentrations of LactiSAL. The bacterial count immediately before
addition of LactiSAL is shown. Counts after exposure to different concentrations of
LactiSAL for several hours are presented on the right. These latter counts were taken
when the stationary phase of growth was reached in the LactiSAL-free control.

2.8 X lO^CFU/ml
9.8 X 10\:FU/ml
6.4 X lO^Cl'U/ml

O

O

4.2 X 10®Cl'U/nil
1.8 X

2.4
3

4

l(A4U/nil

X

5

Time (hours)
0% lactiSAL

0.1 % lactiSAL

0.33% lactiSAL

0.67% lactiSAL

1.0% lactiSAL

2.0% lactiSAL

-+-3.0% lactiSAL

As with the Gram positive bacteria, inhibitory levels of LactiSAL brings about cell
lysis as evidenced by a reduction in culture optical density and a reduction in cell
number when inhibitory concentrations of LactiSAL arc present.
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3.1.7 Oostridium and Bacteroides

Effect of LactiSAL concentration on the strictly anaerobic bacterial genera
Clostridium species and Bacteroides species. For this experiment, spectrophotometer
readings were taken in paraffin oil-sealed broth cultures in test-tubes tubes using a
specially adapted test-tube holder in place of the cuvette holder for the
spectrophotometer.

Figure 3.13. Growth patterns of Clostridia and Bacteroides

Time (hours)
C. aerotolerans
C. lactatifermentans
C. difficile

C. colicanis
' C. caproicum
B. vulgatus

On the basis of the patterns in Figure 3.13, Clostridium difficile ATCC43593 and
Bacteroides vulgatus DSMZ1447 were been selected for the challenge experiment.
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Figure 3.14 Growth of Clostridium difficile ATCC43593 in the presence of inhibitory
and suh-inhihitory concentrations of LactiSAI.. The bacterial count immediately
before addition of IMCtiSAL is shown. Counts after exposure to different
concentrations of IMCtiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL-free control.

0.9
0.8

0.7
0.6

Q 0.5
O 0.4
0.3
0.2

0.1
0

5

6

7

8

9
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12

Time (hours)
—♦—()% lactiSAL
0.033% lactiSAL
-^0.1% lactiSAL

-H^-0.01% lactiSAL
0.067% lactiSAL
-^0.133% lactiSAL

In the case of Clostridium difficile ATCC43593, concentrations of LactiSAL of 0.1%
or greater bring about lysis of bacterial cells as evidenced by the reduction in optical
density and the concomitant reduction in viable cell numbers as ascertained by plate
count.
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Figures.15 Growth of Bacteroides Vulgatiis DSMZ1447 in the presence of inhibitory
and suh-inhihitory concentrations of LactiSAL. The bacterial count immediately
before addition of ImcuSAL is shown. Counts after exposure to different
concentrations of LactiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL -free control.

0.7
0.6

0.5

O 0.4

O 0..5

0.2
0.1

0

Time (2hoiirs)

O.OJ % lactiSAL -A- 0.033% lactiSAL
0% lactiSAL
0.067% lactiSAL -5K-0.1% lactiSAL -•-0.133% lactiSAL
In the case of Bacteroides Vulgatus DSMZ1447, concentrations of LactiSAL of
0.033%^ or greater bring about lysis of bacterial cells as evidenced by the reduction in
optical density and the concomitant reduction in viable cell numbers as ascertained by
plate count.

93

3.1.8 Staphylococcus
Tables.7 Effect of LaciiSAL concentration on colony size of Staphylococcus species
on BHI medium.
Species

S. aureus
M249318
S.aureus
M250594
S.aureus
ATCC:25923
S.aureus
M25176()
S.aureus
DPC5246
S.aureus
M231003
S. aureus
M253472

Colony Diameter (mm)
0.5 %
I>actiSAL
(1:200)

0.4 %
l.actiSAL
(1:250)

0.33 %
I^ctiSAl
(1:300)

0.2 %
l^ctiSAL
(1:500)

0.1 %
I^cliSAl.
(1:1000)

0.067 %
I^cliSAI.
(1:1500)

0%
I>acliSAl.
(control)

0

0

0

0.2

0.5

0.5

1.0

0

0

0

0.2

0.2

0.5

1.5

0

0

0

0.2

0.2

0.5

1.5

0

0

0

0.2

0.5

1.5

2.0

0

0

0

0.2

0.5

1.5

1.5

0

0

0

0.2

0.2

0.5

1.5

0

0

0

0.2

0.5

1.0

1.5

LactiSAL concentrations of 0.33% and greater are completely inhibitory to all the
above Staphylococcus. Growth of Staphylococcus occurs at 0.2% maximum.
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Figure 3.16. Comparison of growth rates of the different strains of Staphylococcus
aureus in BHI broth.

3

4

7

5

Ti n®( hours)
aureus
S aureus
■*“S aureus
“^S aureus

49318
S aur eus
AT(I25923
S aureus
[PC5246 ^ a aureus
l\^53472

N250594
N$51760
N231003

Staphylococcus aureus ATCC25923 was challenged with LactiSAL at a range of
concentrations which inhibited growth and which allowed colony formation to occur,
namely 0.033%, 0.067%, 0.1%, 0.2% and 0.33%. The results are shown in Figure
3.17.
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Figure 3.17 Growth of Staphylococcus aureus ATCC25923 in the presence of
inhibitory and sub-inhihitory concentrations of LactiSAL. The bacterial count
immediately before addition of IMctiSAL is shown. Counts after exposure to different
concentrations of LactiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL -free control.

In the case nf Staphylococcus aureus ATCC25923, concentrations of LactiSAL of
0.2% or greater bring about lysis of bacterial cells as evidenced by the reduction in
optical density and the concomitant reduction in viable cell numbers as ascertained by
plate count.
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Figure 3,18 G rowth of Staphylococcus aureus DPC5246 in the presence of inhibitory
and sub-inhibitory concentrations of LactiSAL. The bacterial count immediately
before addition of LactiSAL is shown. Counts after exposure to different
concentrations of LactiSAL for several hours are presented on the right. These latter
counts were taken when the stationary phase of growth was reached in the
LactiSAL -free control.
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3.1.9 Bacillus
Table 3.8 Effect of LaciiSAL concentration on colony size of Bacillus subtilis
ATCC6633 on BHI medium.

Species

B. subtilis
A'r('C6633

Colony Diameter (mm)
0.5 %
l^actiSAI.
(1:200)

0.4 %
L^actiSAI.
(1:250)

0.33 %
I^cliSAI (1:.300)

0.2 %
I.acliSAL
(1:500)

0.1 %
IxictiSAL
(1:1000)

0.067 %
IxictiSAI.
(1:1500)

0%
I^ctiSAl.
(control)

0

0

0

0

5.0

5.0

5.0

LactiSAL concentrations of 0.2% and greater are completely inhibitory to the B.
subtilis ATCC6633. Growth of B. subtilis occurs at 0.2% maximum.
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Figure 3.19 Growth of Bacillus suhtilis ATCC6633 in the presence of inhibitory and
suh-inhihitory concentrations of LactiSAL. The bacterial count immediately before
addition of LactiSAI. is shown. Counts after exposure to different concentrations of
LactiSAL for several hours are presented on the right. These latter counts were taken
when the stationary phase of growth was reached in the LactiSAL-free control.

1.4
1.2

? ^
o 0.8
^ 0.6

O 0.4
0.2
0

Time (hours)
0% lactiSAL

0.()()1% lactiSAL

0.033% lactiSAL

0.067% lactiSAL

^0.1% lactiSAL

0.2%^ lactiSAL

Concentrations of LactiSAL of 0.1% or greater bring about lysis of bacterial cells as
evidenced by the reduction in optical density and the concomitant reduction in viable
cell numbers as ascertained by plate count.
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3.1.10 Salmonella

Table 3.9 Effect of l.actiSAL concentration on colony size of Salmonella enterica
species on BHI medium.

Species

S .enterica serovar
Newport
'r46
.S' .enterica serovar
104
S .enterica 61104

Colony Diameter (mm)
4.0 %
liictiSAi.
(1:25)

3.0%
I^acliSAI.
(1:33)

2.0 %
I^ctiSAL
(1:50)

1.0%
IxictiSAJ
(1:100)

0.5 %
l^actiSAI,
(1:200)

0.33 %
IjicliSAl.
(1:300)

0%
I^ctiSAl.
(control)

0.5

1.0

1.0

1.0

2.0

2.0

2.0

0.5

1.0

1.0

1.0

1.5

2.0

2.0

0.5

1.0

1.0

1.5

1.8

2.0

2.0

The results were broadly similar to those previously seen with the E. coli strains.

Figure 3.20. Comparison of growth rates of the different species of Salmonella
enterica in BHI broth.

S . newport T46

S. virchow 104

S. enterica 61104

Figure 3.21 Growth of S. newport T46 in the presence of inhibitory and
sub-inhibitory concentrations of LactiSAL. The bacterial count immediately before

100

addition of IMctiSAL is shown. Counts after exposure to different concentrations of
LactiSAL for several hours are presented on the right. These latter counts were taken
when the stationary phase of growth was reached in the LactiSAI.-free control.

As previously seen with the Gram-positives, inhibitory levels of LactiSAL brings
about cell lysis as evidenced by a reduction in culture optical density and a reduction
in cell number at 1%. It causes a significant drop in cell numbers at 3% where the titre
was reduced from 9.3 x 10 to 1.0 x 10 . The drop in optical density observed where
3% LactiSAL was included indicates that cell lysis is occurring at this level.
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3,1.11 Helicobacter pylori
Two isolates of the Gram-negative microaerophillic gastritis-causing bacterium from
Cork University Hospital were employed and evaluated in accordance with the
previously used protocols. The bacterium was completely inhibited at 0.67%
LactiSAL as shown in Table 3.10. Growth rates were then evaluated in broth under
microaerophillic conditions and the data is presented in Fig 3.22.

Table 3.10 Effect of LactiSAL concentration on colony size of Helicobcter pylori
species on BHl-Blood a^ar.

Species

Colony Diameter (mm)
2.0 %
I .act is AL
(1:50)

1.0%
l.actiSAI
(1:100)

0.67 %
LictiSAI,
(1:150)

0.33 %
IxictiSAI.
(1:300)

0.1 %
I.actiSAL
(1:1000)

0 % UcliSAL
(control)

0

0

0

0.2

0.5

1.5

0

0

0

0.2

0.5

1.5

//. pylori
MS 2583

//. pylori
MS4141

LactiSAL concentrations of 0.33% and greater are completely inhibitory to the
Helicobcter pylori species. Growth of Helicobcter pylori species occurs at 0.33%
maximum.

102

Figure 3.22. Comparison of growth rates of the different species of Helicobcter pylori
in BHI-Blood medium

H DvI or i IV62583

H Dviori
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Figure 3.23 G rowth of H. pylori MS2583 in the presence of inhibitory and
snh-inhihitory concentrations of ImcuSAL. The bacterial count immediately before
addition of LactiSAL is shown. Counts after exposure to different concentrations of
TactiSAL for several hours are presented on the right. These latter counts were taken
when the stationary phase of growth was reached in the LactiSAL-free control.

In the case of H. pylori MS2583, concentrations of LactiSAL of 0.67% or greater
bring about lysis of bacterial cells as evidenced by the reduction in optical density and
the concomitant reduction in viable cell numbers from 5.6 x lO^CFU/ml to 3.1 x
lO^CFU/ml
as ascertained by plate count.
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3.1.12 Enterobacter sakazakii
One isolate of the Gram-negative bacterium from DSMZ was employed and evaluated
in accordance with the previously used protocols. The bacterium was completely
inhibited at levels higher than 2.0% LactiSAL as shown in Table 3.11. Growth rates
were then evaluated in broth under microacrophillic conditions and the data is
presented in Fig 3.24.

Table 3.11 Effect ofl.actiSAL concentration on colony size of Enterobacter sakazakii
species on BHI agar.
Colony Diameter (mm)

Species

0.67 %
liictiSAL
(1:150)

0.53 %
IxicliSAI.
(1:300)

0.1 %
I^cliSAL
(1:1000)

0% I^ctiSAL
(control)

(1:50)

1.0 %
l.actiSAl,
(1:100)

0.1

1.0

1.5

2.0

3.0

3.0

2.0 %

1 .actiSAI,
I’’.sakazakii
DSMZ4485
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Figure 3.24 Growth of Enterobacter sakazakii DSMZ4485 in the presence of
inhibitory concentrations of ImcUSAL.

In the case of Enterobacter sakazakii DSMZ4485, concentrations of LactiSAL of 2.0
% or greater bring about lysis of bacterial cells as evidenced by the reduction in
optical density and the concomitant reduction in viable cell numbers from 5.9 x
lO^CFU/ml to 4.5 x lO^CFU/ml as ascertained by plate count.
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3.1.13 Yeast: Candida albicans

Two Candida albicans isolates were obtained from human infection cases in Cork
University Hospital and a third isolate was obtained from DSMZ. These three
representative strains were employed and evaluated in accordance with the protocols
used with bacteria above. The yeast isolates were completely inhibited at LactiSAL
levels higher than 0.1% as shown in Table 3.12. This is comparable to the level of
LactiSAL tolerated by the Gram-positive bacterium Lactococciis lactis. Growth rates
of the yeast were then evaluated in broth and the data is presented in Fig 3.25. Growth
in the presence of different concentrations of LactiSAL was also tested and these
results are presented in Fig 3.26.

Table 3.12 Cffcct of LactiSAL concentration on colony size oj Candida albicans
species on Sahouraud medium

Species
C. albicans
DSMZ1386

0.2 %
I.actiSAL
(1:500)

0.1.33 %
1-actiSAl
(1:7.50)

0.1 %
I^ctiSAI
(1:1000)

0.067 %
liictiSAI^
(1:1.500)

0.033 %
liictiSAL
(1:3000)

0.01 %
IxictiSAI.
(1:10000)

0%
liictiSAL
(control)

0

0

0

0.2

0.5

0.8

1.0

0.1

0.2

0.5

0.8

1.0

0

0.2

0.2

0.8

1.0

C. albicans
MS21286

0

C. albicans
MS212y2

0

0
0

LactiSAL concentrations of 0.133% and greater are completely inhibitory to all the
above Candida albicans. Growth of Candida albican occurs at 0.133% maximum.
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Figure 3.25. Comparison of growth rates of the different species of Candida albicans
in Sahouraiid medium.
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Figure 3.26 G rowth of C. albicans DSMZ1386 in the presence of inhibitory and
sub-inhibitory concentrations of iMctiSAL.
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3.1.14 Yeast: Saccharomvces cerevisiae
One Saccharomyces cerevisiae isolate was obtained from DSMZ. This yeast isolate
was completely inhibited at LactiSAL levels higher than 0.1% as shown in Table 3.13.
This is comparable to the level of LactiSAL tolerated by the Candida albicans yeast
(and also the Gram-positive bacterium Lactococcus lactis). Growth rates of this yeast
were then evaluated in broth in the presence of different concentrations of LactiSAL
and the data is presented in Fig 3.27.

Table 3.13 Effect of I.actiSAL concentration on colony size of Saccharomyces
cerevisiae species on Saboiiraud medium.

Species

S. cerevisiae
DSMZ 1333

Colony Diameter (mm)
0.133 %
I iictiSAl,
(1:7.30)

0.1 %
UctiSAl
(1:1000)

0.067 %
l^ctiSAl(1:1.300)

0.0.33 %
I actiSAL
(1:3000)

(1:100(X))

0

0.2

0.8

1.0

1..3

0.01 %

1 actiSAF

0% UctiSAI.
(control)

1.5

LactiSAL concentrations of 0.133% and greater are completely inhibitory to
Saccharomyces cerevisiae DSMZ1333. Growth of Saccharomyces cerevisiae
DSMZ1333 occurs at 0.133% maximum.

no

Figure 3.24 Growth of Saccharomyces cerevisiae DSMZ1333 in the presence of
inhibitory concentrations of LactiSAL.
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3.2 Effect of pH on LactiSAL activity (usm2 Lb.

iohnsonii^.

At the time of execution of this work, LactiSAL was intended for ingestion by
humans. Thus it would experience a range of different pH environments as it would
move through the gastrointestinal tract. To evaluate the effect of pH, phosphate
buffers were adjusted to a range of pH values (from 1.0, 2.0. 3.0, 4.0, 5.0, 6.0, 7.0, 8.0
and 9.0). LactiSAL was exposed to each of these pHs for 2 hours. Then the different
pH-treated LactiSAL batches were added to MRS agar to final concentrations of
0.133%, 0.2%, 0.33% and 1.0%. These are the concentrations which were previously
shown to be inhibitory to Lh. johnsonii DSMZ10533. Colony sizes were then
evaluated.

Table 3.14 Effect of 0.133% L actiSAI. (pH 1.0 to pH 9.0 ) on colony size of
Lactobacillus johnsonii on MRS agar medium
Colony Diameter (mm)
No

1.5

0.133% I.actiSAl.pl 15.0

0.5

0.133 % I.acliSAl.pl11.0

1.0

0.133 % l.acliSAI.pH6.0

0.5

% 1 .actiSAI.pl 12.0

0.8

0.133 % I.actiSAI.pH7.0

0.5

0.133 % I.actiSAl.pll3.0

0.8

0.133 % I.actiSAI.pll8.0

0.8

0.133 % lxictiSAl.pl 14.0

0.5

0.133 % l.actiSAI.pH9.0

1.0

0.133

l^cliSAL
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Table 3.15 Effect of 0.2% LactiSAL (PHl.O to PH9.() )on colony size of Lactobacillus
Johnsonii on MRS agar medium

Colony Diameter (mm)
No

l>actiSAl.

1.5

0.2% l^ctiSAl.pH3.0

0.2

0.2% I^ctiSAJ.pHl.O

0.2

0.2% I^ctiSAI.pHO.O

0.2

0.2% l^ctiSAL pH2.0

0.2

0.2

% I^ctiSALpHT.O

0.2

0.2% LactiSAI.pH3.0

0.2

0.2

% I^ctiSAI.pHH.O

0.2

0.2% l^ctiSALplW.O

0.2

0.2

% 1 actiSAL pH9.0

0.2

Table 3.16 Effect of 0.33% L actiSAL (pH LO to pH 9.0 on colony size of
Lactobacillus Johnsonii on MRS agar medium

Colony Diameter (mm)
1.5

0.33% IiicliSAI.plis.o

0

0.33 % I .actiSAL pi 11.0

0

0.33 % liiciiSALpIlO.O

0

0.33 % IiictiSAI, pI12.0

0

0.33 % I iictiSAI, pi 17.0

0

0.33 % IiictiSALpll3.0

0

0.33 % I.acliSALpI18.0

0

0.33 % I.acliSAL pIW.O

0

0.33 % IiictiSAl.pl 19.0

0

No

liicliSAL

Table 3.17. Effect of 1.0 % LactiSAL (pH LO to pH 9.0) on colony size of
Lactobacillus Johnsonii on MRS agar medium

Colony Diameter (mm)
No

liictiSAI.

1.5

1.0% l.actiSALpH5.0

0

1.0% I.actiSAI.pHl.0

0

1.0% I.actiSAl.pH6.0

0

1.0% liictiSAL pH2.0

0

1.0% liictiSAl.pHT.O

0

1.0 % liictiSAI. pH3.0

0

1.0% liictiSAl.pHS.O

0

1.0% I.actiSALpH4.0

0

1.0% I.actiSAl.plI9.0

0

Figure 3.27 Growth of Lb. johnsonii DSMZ10533 in the presence of 1.0% LactiSAL
(pH 1.0 to pH 9.0).
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♦- 0% LactiSAL
■-l.()%LactiSALPHl
1.0 % LactiSAL PH2
1.0 % LactiSAL PH3
1.0 % LactiSAL PH4
1.0 % LactiSAL PH5
1.0 % LactiSAL PH6
1.0 % LactiSAL PH7
1.0% LactiSAL PH8
1

2

3

4

5

6

7

1.0% LactiSAL PH9

Time (hours)

pH 1.0

1.4 X l(LCFU/ml pH4.0

1.2 X lOTFU/ml pH7.0 8.1 X KLCFU/ml

pH2.0 4.1 X KFCFU/ml pH5.0

1.0 X lO'CFU/ml pH8.0 4.9 X KLCFU/ml

pH3.0 2.2 X KLCFU/ml pH6.0 3.6 X KLCFU/ml pH9.0 6.5 X KLCFU/ml

The data in Figure 3.27 indicates that 1% LactiSAL (pH 1.0 to pH 9.0) all inhibits
growth, bringing about a reduction in cell numbers, and causing a significant drop in
cell numbers. The titre was reduced from 6.3 x lO'"’ to the values shown in the table
under the graph. The reductions in cell number brought about by the different
LactiSAL pH-batches were used to obtain an arbitrary activity value (ACFU) for the
LactiSAL.

Figure 3.28 Effect of pH on ImcuSAL activity (summary). The graph shows pH versus
ImcuSAL arbitrary activity values which were derived from the reduction in Lh.
johnsonii cell numbers (ACFU).
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10"
0
03

>

o

<

PH

Greatest activity was evident at pH 5 with a ACFU of l(r. At pHs 1.0 and 9.0 the
ACFU was approximately lO'^. Thus while extremes in pH do not inactivate
LactiSAL, its antimicrobial efficacy is reduced. Thus higher concentrations of
LactiSAL would need to be employed to maintain antimicrobial efficacy in pH
extreme environments.
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3.3 Duration of exposure to LactiSAL concentrate.

It was of interest to ascertain how long a bacterial cell needed to be exposed to
LactiSAL to mediate cell death. Thus, the following experiment was designed
whereby LactiSAL was added to actively growing cultures of Lactobacillus johnsonii
DSMZ1()533, E. coli DSMZ787, E. coli DSMZ1()58, Lactococcus lactis 1VIG1363,
Enterococcus fecium, DSMZ13589 and Bifidobacterium bifidum DSMZ2()456. With
these cultures, LactiSAL was added at the appropriate inhibitory concentration and
allowed to act for 5 minutes and 30 minutes. After 5 minutes, 1 ml of culture was
removed and diluted decimally in quarter-strength Ringers solution and plated out on
the appropriate agar medium. The dilution process has the effect of immediately
removing exposure to lactiSAL. A 1 ml aliquot was also removed after 30 minutes
and again diluted and plated out. Plate counts after 5 minutes and 30 minutes are
shown in Table 3.17. Control plate counts were obtained immediately prior to
addition of LactiSAL. An example of this experiment with Lactobacillus johnsonii
DSMZ10533 is shown in Figure 3.29 where the exposure was carried out at two
stages in the growth cycle (mid-log and stationary phase). The same approach was
used for the other genera tested, although a figure is not necessary to demonstrate this.
The results of exposure time is summarised in Table 3.18.
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Figure 3.29 Effect of duration of exposure to 0.4% lactiSAL on Lactobacillus
johnsonii DSMZ10533 at two stages in the growth cycle (mid-log and stationary
phase)
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Table 3.18 Effect of duration of exposure to LactiSAL on plate counts of Lactobacillus
jolinsonii DSMZJ()533, E. coli DSMZ787, E. coli DSMZI()58, Lactococcus lactis
MG1363, Enterococcus fecitim, DSMZl3589 and Bifidobacterium bifidum
DSMZ2()456. The first exposure was carried out at mid-log and the second at
stationary phase (2'‘^ column)
Plate counts after exposure to LactiSAL
liictiSAI. absent

l^ctiSAL exposure

(control)

Species
Eschericha coli

1st

8.9

X

DSMZ787

2nd

2.8

X 1(T

Eschericha coli

for

I^ctiSAI.. exposure

5m in

for 30niin

lO^CFU/ml

4.5

X

10" CFU/ml

1.6x 10^ CFU/ml

CFU/ml

2.4

X

1 o’CFU/ml

9.3

1st

6.2 X 10"CFU/ml

1.4

X

10" CFU/ml

7.8x lO'^ CFU/ml

l)SMZl()58

2nd

2.1

10^ CFU/ml

2.3

X

10" CFU/ml

1.2 X 10" CFU/ml

L. lactis

1st

1.2 X 10^ CFU/ml

4.6

X

10" CFU/ml

2.5x 10^ CFU/ml

MG1863

2nd

3.2 X 1 o'" CFU/ml

7.4

X

10" CFU/ml

5.4

Ent.faeciuni

1st

2.4

X

lO-CFU/ml

4.0 X lO" CFU/ml

1.0 X 10" CFU/ml

DSM/J3589

2nd

2.7

X

10^ CFU/ml

1.2 X 10" CFU/ml

2.0 X 10" CFU/ml

Lh. jolinsonii

1st

2.5

X

l()\d^'U/ml

4.9

3.6

l)SMZ10S33

2nd

2.2 X loVlFU/ml

6.9

Uil’.bificluin

1st

9.2 X 10“cFU/ml

2.4 X 1(F CFU/ml

2.0 X lO^FU/ml

DSMZ2()456

2nd

2.8 X loVFU/inl

2.1

1.5

X

X

10" CFU/ml

ssp. cremoris

X

10"('FU/ml

X

lO-CFU/ml

X

lO" CFU/ml

4.8

X

10“*CFU/ml

X

10“* CFU/ml

X

10’CFU/ml

X

UF CFU/ml

The results in Table 3.18 clearly show that 5 minutes exposure to LactiSAL generally
brings about a lOO-fold reduction in cell numbers. The 30 minute exposure generally
brings about up to a 10,000 fold reduction in cell numbers.

118

3.4 Lactate Dehvdro2enase assay to indicate cell
leakage
Lactate dehydrogenase (LDH) is an intracellular enzyme whose detection in culture
supernatants is an indicator of cell leakage. The enzyme is an oxidoreductase which
catalyzes the interconversion of lactate and pyruvate. LDH is the most frequently
measured enzyme to evaluate the presence of tissue or cell damage or cell lysis in
cells. Two tubes of 1% L.lactis (one containing 0.1% LactiSAL, and another as a
control ) were grown at 3(LC for 4 hours and transferred to 37‘’C for 1.5 hours then
subjected to the LDH assay to ascertain whether or not cell lysis had taken place.
Results are shown in Table 3.19. The data is presented as OD (34()nm) where a
decrease in OD over three minutes indicates LDH activity and therefore cell lysis. The
more rapid the decrease over the three minutes, the greater the extent of lysis. The
calculation was done as follows:
A34()/min x3xDilution factor

=

unit/ml sample

6.27x0.1x1
A340/min: calculate from spec.
Control = 0.03987 unit / ml
Contain 0.1%LactiSAL = 0.1611 unit / ml
Activity is expressed as unit per ml of extract, where one unit is defined as the amount
of enzyme that catalyses the oxidation of IpM NADH per minute.
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Table 3.19. LDH assays, shown ()I)(34()nm) readings over three minutes. The more
rapid the decrease in OD over the three minutes, the greater the extent of lysis.
Sample

0 min

1 min

2 min

3 min

1.074

1.065

1.057

1.049

1.103

1.069

1.035

1.002

Control (L. lactis in
presence of no LactiSAL)
L. lactis in presence of
0.1% LactiSAL

The control sample shows hardly any reduction in OD over the three minutes (1.074
to 1.049) indicating minimal leakage of the enzyme LDH. The test sample shows a
significant reduction in OD over the three minutes (1.103 to 1.002) indicating
presence of the enzyme LDH and thus leakage of cellular contents. This result
indicate that the lipoprotein LactiSAL causes cellular leakage

3.5 Effect of LactiSAL on microbial inhabitants of
porcine intestine.

Isolation of fresh porcine gastrointestinal tract material containing typical viable
bacteria. A 24-week old pig of weight 97 kg was slaughtered and its gastrointestinal
tract (GIT) removed. Samples were removed from the GIT at four sites, namely the
stomach, the jejunum, the terminal ileum, and the descending colon. The pH of the
material at each location was as follows: stomach pH 5.25; jejunum pH 6.27; terminal
ileum pH 6.34 and descending colon pH 6.18 (the high stomach pH is due to the animal
fasting prior to slaughter). Samples were kept on ice and used within 24 hours of
slaughter so that there was minimal die-off of GIT microbial inhabitants.
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Colon

Stomach

Figure 3.30. L ocations in porcine GIT from which samples were removed are
indicated with a red asterix.

LactiSAL (1ml) was added to final concentrations of 0.1% and 0.4% to 9 ml samples
of GIT material in test-tubes and mixed using a vortex mixer. In negative controls, 1
ml water was added instead of lactiSAL solution. The colon sample, being semi-solid,
was diluted 5-fold in quarter-strength Ringer solution before addition of LactiSAL.
After exposure to LactiSAL, 1ml was withdrawn from samples, sequentially diluted
10-fold and spread-plated on different agar media to facilitate enumeration of (a) total
culturablc

bactera:

brain

and

heart

infusion

agar;

(b)

bifidobacteria:

MRS-cystcinc-mupirocin; (c) lactobacilli: MRS; (d) Clostridia: reinforced clostridial
medium. Plates were incubated anaerobically for at least 48 h after which colonics
were enumerated.
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Table 3.20. Enumeration oj selected microbial inhabitants of gastrointestinal tract in
presence and absence of LactiSAL (Trial 1).

GIT location

Stomach

Duodenum

Terminal
Ileum

Descending
Colon

Bacterial growth
medium

Colony count (CFU/ml) *
0% I^ctiSAI.

0.1% l^ctiSAI.

BHI (general
anaerobic bacteria)
MRS (lactobacilli)

1.1 X 10^

-

5.1 X 10'

-

-

-

MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium
BHI (general
anaerobic bacteria)
MRS (lactobacilli)

-

-

-

-

-

-

6.7 X 10'^

-

1.8 X i(?

-

-

-

-

-

-

-

-

-

6.9 X 10^

3.1 X 10^

4.5 X 10^

2.9 X lO"'

6.2 X 10'’

5.0 X 10'’

1.0 X !()'

8.9 X 10-

3.7 X 10"

MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium
BHI (general
anaerobic bacteria)
MRS (lactobacilli)
MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium
BHI (general
anaerobic bacteria)
MRS (lactobacilli)
MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium

5.7 X K)-'"

3.8

X 10*’

0.4% IxictiSAI.

9.3 X Id"'

1.6 X 10*'"

4.0 X lO"^

2.0 X 10^"

7.0 X 10“

1.8 X 10'^

6.2 X 10^

2.8 X 10^'

1.2 X 10"

1.1 X 10'’

7.0 X 10^

3.6 X Uf

6.5 X 10^

*Counts arc the average of two platings,
LactiSAL at a final concentration of 0.1% was too low to effect bacterial survival.
Thus subsequent experiments were confined to 0.4% LactiSAL.
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Table 3.21. Enumeration of selected microbial inhabitants of gastrointestinal tract.
Second Pig Experiment (with a 6 week old pig).

GIT location

Bacterial growth
medium

Colony count (CFU/ml) *
0% I^ctiSAL

Stomach

Terminal
Ileum

Descending
Colon

0.4% l^ctiSAl.

1.2 X i(r

8.6 X !()'■

8.7 X

4.6 X 10'’

4.0 X 10-'

2.0 X 10^

3.6 X 10'’

2.3 X 10'’

5.3 X 10^

2.9 X 10^

2.8 X Uf

2.7 X 10''

MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium
BHI (general
anaerobic bacteria)
MRS (lactobacilli)

4.7 X 10-'

3.5 X 10-'

Uxl(F

7.1 X 10^

4.lx lO"

2.8 X 10^

4.2 X 10^

3.7 X 10"

MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium

4.7 X 10'*'

3.1 X 10-‘’

2.1 X 10^

1.3 X 10"

BHI (general
anaerobic bacteria)
MRS (lactobacilli)
MRS-Cys-Mupir.
(bifidobacteria)
Reinforced
clostridial medium
BHI (general
anaerobic bacteria)
MRS (lactobacilli)

*Counts are the average of two platings.
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Table 3.22 Enumeration of selected microbial inhabitants ofgastrointestinal tract. Third
Pig Experiment (with a 6 week old pig).

GIT location

Colony count (CFU/ml) *

Bacterial growth
medium

Terminal

BHI (general

Ileum

anaerobic bacteria)

0% LactiSAL

4.2

0.4% LactiSAL

10*

2.6

X

10*

MRS (lactobacilli)

2.8 X 10*

1.5

X

10*

MRS-Cys-Mupir.

3.0

1.0

X

10^

X

X

10"

(bifidobacteria)
2.2x 10*

1.7x 10'

1.5

X

lO'*

3.9

MRS (lactobacilli)

6.7

X

10'

2.3 X 10^

MRS-Cys-Mupir.

1.6

X

10^

3.5

X

10*

7.0

X

10^

3.7

X

10*

Reinforced
clostridial medium
Descending

BHI (general

Colon

anaerobic bacteria)

X

10*

(bifidobacteria)
Reinforced
clostridial medium
* Counts are the average of two platings

In each of the three trials, colonies appearing on the selective media were examined by
microscopy, catalase, oxidase, API assay and Gram reaction. Colonies on BHI were
generally varied with approximately five different types evident. The colonies on MRS
were uniform and contained rod-shaped bacteria which were Gram positive, catalase
negative and oxidase negative. There were two colony types on MRS-Cys-Mupirocin.

124

The most numerous contained rod-shaped and partial-Y-shaped bacteria which were
judged to be bifidobacteria. These were Gram positive, catalase negative and oxidase
negative. Gram-positive cocci were evident in the other colony type on these plates. The
results above are preliminary, but nevertheless suggest that 0.4% LactiSAL does not have
an inhibitory effect on the bacteria examined under the conditions used above. The
apparent reduced efficacy of LactiSAL against these bacteria in situ is thought to be due
to enzymatic degradation of the LactiSAL in the GIT. Acidic conditions in certain
locations of the GIT could also have reduced its efficacy. The fact that the experiment
showed similar results when done on three separate occasions reinforces this conclusion.
Thus LactiSAL would not be effective as an antibacterial agent if consumed at the
concentration used in the above experiment.
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Section 4
Results Part II

Antimicrobial properties of lactic acid bacteria producing cyclic
dipeptides Cyclo-fL-Phe-L-Pro], CycIo-[L-Leu-L-Pro], and D- and Lphenyl-lactic acid

This section of the results are the subject of a patent

Low molecular weight novel antimicrobial agents previously identified in Lactobacillus plantarum FST1.7.
These are Cyclo (L-Phe-L-Pro) on left; Cyclo (L-Leu-L-Pro) middle; and D and L phenyl lactic acid (right).
Two additional bacteria, namely Weisella cibaria and Lactobacillus amylovorous exhibit stronger
antimicrobial activity than Lactobacillus plantarum FSTl .7. The elucidation of these structures was not part
of this thesis.
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4.1 Confirmation of identity of lactic acid bacterial
strains
The four strains of Lactic acid Bacteria (LAB) which had been previously implicated in
antifungal activity and which had the potential to inhibit bacteria were first checked for
correctness of their identity. All strains were streaked on MRS agar and examined
microscopically using the Gram-stain. All showed the physical properties which were
characteristic of their genus (see Table 4.1). Following this, biochemical tests were
performed on each strain using API and the results are shown in Figure 4.1 and Table 4.1.

Table 4.1 Physical properties of LAB strains with anti-fungal activity.

Genus and
Species

Lactobacillus
pi ant arum

Strain
Number (and
abbreviation
used)
FST1.7 (FST)

Antimicrobials
produced

Phenyllactic acid
Cyclic dipeptide: Cyclo
[L-Leu-L-Pro]
Cyclic dipeptide: Cyclo
[L-Phe-L-Pro]
Phenyllactic acid
Cyclic dipeptide: Cyclo
[L-Phe-L-Pro]

Gram
reaction

Growth
on
MRS

Cell Shape
under
microscope

Positive

Yes

Short
Rod-shaped

Positive

Yes

Short
Rod-shaped

Lactobacillus
piant arum

FST1.9
(TMW)

Lactobacillus
amylovorus
Weissella cibaria

FSTl.la(LA)

Antifungal activity

Positive

FST 1.31
(WC)

Antifungal activity

Positive

Yes

Long thin
Rods

Yes

Rod-shaped
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Figure 4.1 API results of the four producer strains (yellow = positive, purple
negative).

d Lh plantarum FSTl.ld

FST

iji’*

■ V, Ph. plantarum FST1.9 (TMW)

TMW

mm m

Lh. amylovorus FSTl.la

LA
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Weissella ciharia FST1.31
WC

Table4. 2 API results of the four producer strains (\- = positive;

- = negative)

indicating biochemical tests included in the API.

Tube

Substrate

Lb
plan tarum
FST1.7

Lb
plantarurn
PST1.9

0

Control

-

-

Lb
amylovorus
FSTI.la
-

1

Glycerol

-

-

+

-

2

Erythritol

-

-

-

-

3

D-arabinosc

-

-

-

-

4

L-arabinosc

+

+

+

+

5

D-ribosc

+

+

+

+

6

D-xylosc

-

-

-

+

7

L-xylosc

-

-

-

-

8

-

-

-

-

9

D-adonitol
Mcthyl-PD
-xylopyranoside

-

-

-

-

10

D-galactosc

+

+

+

-

11

D-glucose

+

+

+

+

12

D-fructosc

+

+

+

13

D-mannosc

+

+

+

+

14

L-sorbose

-

-

-

-

15

L-rhamnosc

+

+

+

-

16

Dulcitol

-

-

-

-

Weissella
cibaria
FST1.3I
-
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17

Inositol

-

-

-

-

18

D-mannitol

+

+

+

-

19

+

+

+

-

+

+

+

-t-

21

D-sorbitol
Mcthyl-aD
-mannopyranosidc
Mcthyl-aD
-glucopyranoside

+

-1-

-1-

+

22

N-acetylglucosaminc

-1-

+

+

+

23

Amygdalin

+

-f-

+

+

24

Arbutin

-f-

+

+

-1-

25

Esculin ferric citrate

+

-1-

+

+

26

Salicin

+

+

+

•f

27

D-ccliobiosc

+

+

+

+

28

D-maltosc
D-lactose
(bovine origin)

+

+

-1-

+

+

-

+

-f-

+

-

31

D-mclibiosc
D-saccharosc
(sucrose)

+

+

+

+

32

D-trchalosc

+

+

+

-

33

Inulin

-

-

-

-

34

D-mclczitosc

-1-

+

+

-1-

35

+

+

+

-

36

D-rafinosc
Amidon
(starch)

-

-

-

-

37

Glycogen

-

-

-

-

38

Xylitol

-

-

-

-

39

Gentiobiose

+

+

+

+

40

D-turanosc

-1-

+

-

-

41

D-lyxosc

-

-

-

-

42

D-tagatose

-

-

-

-

43

D-fucose

-

-

-

-

44

L-fucosc

-

-

-

-

45

D-arabitol

+

-

-

46

L-arabitol

-

-

-

20

29
30

+

-
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47
48
49

Potassium
gluconate
Potassium
2-Ketogluconate
Potassium
5-Ketogluconate

■f

-r

+

-r

-

-

-

-

-

-

-

-

4,2 Antimicrobial activitv of LAB strains (overlay method)
Lactic acid bacteria (LAB) arc known to have antimicrobial activity, part of which is
due to their acid-producing ability. The inhibitory potential of LAB was determined
by using overlay assay, where the overlay contained the target bacterium against
which the LAB were being evaluated. The four LAB strains (see Table 4.1) were
inoculated in triplicate onto buffered MRS agar plates and incubated under anaerobic
conditions at 30‘’C for 48h. The plates were overlaid with soft agar containing 1%
target bacteria and incubated aerobically at 37'’C for 24h. The sizes of the zones of
inhibition around the triplicate LAB colonics were recorded in Table 4.3.
The main antimicrobial effect by LAB results from the production of lactic acid and
concomitant reduction of pH. Nevertheless, these particular LAB produce various
additional antimicrobial compounds, in particular Lactobacillus plantanim FST1.7
(FST) which has been proven in another study to release Phenyllactic acid. Cyclic
dipeptide:

Cyclo-|L-Lcu-L-Pro|,

and

Cyclic

dipeptide:

Cyclo-[L-Phc-L-Pro|.

Buffered media were used to eliminate antimicrobial effect from the lactic acid. A
Lactobacillus amylovorus DSMZ1359 strain (which is known not to produce
inhibitory compounds) was used as negative control.
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Table 4.3. Zone of inhibition around the LAB colonies on agar medium overlayed with
various target bacteria.

pH
tolerance
of target
strain

5.0

3.0-7.0

7.0-7.3

1

5.0-10.0

4.2-9.3

13:

Salmonella

5.0 cm

6.0 cm

3.0 cm

4.0 cm

1.5 cm

j—

enterica

5.0-8.7

Newport T46

Enterobacter

4.0 cm

3.0 cm

2.0 cm

3.0 cm

1.0 cm

sakazakii
DSMZ4485

pH of broth
after growth
of producer

7.0

5.11

5.09

5.34

5.30

5.34

A clear zone of inhibition around the LAB colonies is shown in the photographs
above. To recognise the effect of lactic acid, the pfls of broths after complete growth
of producer strains (and negative control strain) were recorded and these ranged from
5.09-5.34. It is evident that the clear zones around the four producer strains are larger
than the clear zones around the negative control strain. The pH tolerance of target
strains are indicated at the right side and it indicates that all the target bacteria are not
significantly inhibited by the lactic acid-related pH drop which results from growth of
the producer strain. Thus all four strains of producer inhibited all target bacteria and
the inhibition was independent of acid production.
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43 Assays using purified antimicrobial agents

CXX)F

HO

H

Low molecular weight novel antimicrobial agents have been previously identified in
Lactobacillus plantanim FST1.7. These are Cyclo (L-Phe-L-Pro) on left; Cyclo
(L-Leu-L-Pro) middle; and D and L phenyl lactic acid (right). These are available as a
result of Chemical Synthesis.

43,1 Antimicrobial activity of PhenvUactic acid by plate
assays
To evaluate the effect of purified Phenyllactic acid, /:. coli PI 432 was used as a target
bacterium. Briefly, 0.1 ml of fully growth culture spread on BHl agar plates. Filter
discs containing 15 mg/ml and 25 mg/ml of Phenyllactic acid were added on the
plates. Discs containing similar concentrations of lactic acid (15 mg/ml and 25 mg/ml)
were used as negative controls. Plates were incubated at 37‘’C for 24h. The resulting
zones of inhibition around the disc arc shown in Figure 4.2.

Figure 4.2 Disc diffusion assays with different concentrations of L- phenyllactic acid
and lactic acid (control) with E. coli PI432 as target bacterium. Each disc is present
in duplicate.
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Phenyllactic
acid
15ing/ml:
2.0 cin zone of
inhibition

lactic acid
15mg/inl:
No inhibition

Phenyl lactic
acid
25mg/ml;
5.0 cm zone
of inhibition

lactic acid
25ing/ml:
2.0 cTn zone
of inhibition

It is evident that the zone of inhibition of E. coli growth around the Phenyllactic acid
discs is greater than the zones caused by lactic acid at the same concentrations. Thus,
phenyllactic acid has antimicrobial activity which is much stronger than lactic acid.

433 Antimicrobial activitv of pure compounds by microtitre
plate assays
Microtitre plate assays were conducted using a variety different target bacteria and
yeast including E. faecalis, E. coli, MRSA, Enterohactor, Helicobacter, Listeria,
Salmonella and Candida. A variety of concentrations of the different inhibitors were
used. The results are presented in Figs 4.3 to 4.6.
Figure 4.3 Growth patterns of different bacteria (yeast) in the presence of different
concentrations of Phenyllactic acid ranging from 2.5mglml to 12.5mg/ml
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l£.faecalis

3£.coli
2J{elicobacter

4J^isteria

5MRSA
7£nterobactor
6.Salmonella

Phcnyllactic acid ccmccntrations of 3.75 mg/ml and greater are completely inhibitory
to all the above target bacteria. Thus the inhibitory assays concentrated on lower
levels of phenyllactic acid, i.c. from ().5mg/ml to 12.5mg/ml and the resulting growth
patterms are shown in Figure 4.4.
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Figure 4.4 Growth patterns of different bacteria and in the presence of different
concentration of Phenyllactic acid ranging from O.Smglml to ll.Smglml
lyllactic
2-No inhibitor 4-0.5
6-1.0
8-2.5
10-7.5
(mg/ml^-12.5
------------ 1-Blank
3-0.25
5-0.75
7-1.25
9-5.0
11-10.0

As shown above, Phenyllactic acid concentrations of 5mg/ml and greater arc
completely inhibitory to all above target bacteria. Growth of target bacteria occurs at
2,5 mg/ml maximum. Idsteria, MRSA, and E. faecalis arc Gram-positive bacteria.
Enterohacter, Salmonella, E. coli, and Helicobacter arc Gram-negative bacteria.
5mg/ml phenyllactic acid is equally inhibitory to both groups.
Next, it was of interest to remove the pH effect associated with phenyl lactic acid, as
this probably contributes to the inhibition associated with this compound. As shown
above in Fig 4.4, concentrations of 5 mg/ml to 12.5 mg/ml of phenyllactic acid arc
completely inhibitory and thus these were chosen for next assay. In this assay these
concentrations of phenyllactic acid were compared with 5 mg/ml and 15 mg/ml of
neutralized phenyllactic acid (pH6~7). Identical concentrations of lactic acid
(neuralized and unncutralised lactic acid) were used as controls.
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Figure 4.5 Growth patterns o f different bacteria (yeast) in the presence of 5, ISmglml

of Phenyllactic acid (PIA); 5,]5mglml neutralized PIA; 5, ISmglml lactic acid (LA)
and 5, ISmglml neutralized IA.

1.Blank , 2.LA 5mg/ml, 3.LA 15mg/ml, 4.LA 5mg/ml pH6~7,5.LA 15mg/ml
pH6'-7,

6.PLA 5mg/ml, 7.PLA 15mg/ml, 8.PLA 5mg/ml pH6~7, 9.PLA

15mg/ml pH6~7

2

1
E.coli
MRSA
Salmonella
Candida

A
B
ip
c
D

3

4

5

p P..
/
~n.

)

As shown in Fig 4.5, 5 mg/ml and 15 mg/ml of lactic acid inhibited bacterial growth
but did not inhibit yeast growth. As expected, 5 mg/ml and 15 mg/ml phenyllactic
acid inhibited all bacterial and yeast growth. As one might expect, 5 mg/ml and 15
mg/ml of neutralized lactic acid did not have any inhibitory properties. But in the case
of neutralized phenyllactic acid, while 5mg/ml didn’t inhibit growth, 15mg/ml was
slightly inhibitory. This inhibition is investigated further in section 4.3.4.
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Figure 4.6 Growth patterns of E.coli, MRSA, Salmonella and Candida in the presence
of 10 mg!ml, 20 mg!ml and 25mg!ml of Cyclic dipeptide (LeuPro). In channel 12, the
high concentration of dissolved Cyclic dipeptide is contributing to the absorbance.

1. No inhibitor
lOmg/ml

lO.Cyclic dipcptide (LeuPro)

ll.Cyclic dipcptide (LeuPro) 2()mg/ml

12.Cyclic dipcptide

(LeuPro) 25mg/ml

Salmonella
Candida

Cyclic dipcptide (LeuPro) concentrations of 2()mg/ml and greater arc completely
inhibitory to all above target bacteria (yeast). Growth of target bacteria and yeast
occurs at lOmg/ml.
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43 A Antimicrobial activity of pure antimicrobial
compounds in liquid cultures in glass
The data in figures 4.3-4.6 were derived from microtitre plate assays. This involved
using plastic microtitre dishes. One difficulty with this methodology is that the
antimicrobial compounds are known to have some affinity for plastic. Thus, the data
above can only be interpreted as preliminary. More accurate data can be derived by
conducting growth assays in glass containers Logistically, it’s not possible to assay a
large number of bacterial strains in glass as microtitre systems arc not available in
glass. In addition, from the results recorded up to now, the inhibitory concentrations
arc similar for all bacterial genera and yeast. Thus, in the case of L-Phcnyllactic acid
only E. coli was used to explore the antimicrobial effects during growth in broth in
glass containers.

4.3.4.1 Growth of E.coli strains in presence of L-Phenyllactic acid
and cyclic dipeptides
It has been shown above in Figure 4.5 that 5 mg/ml and 15 mg/ml of lactic acid
inhibited bacterial growth. The same was the case for 5 mg/ml and 15 mg/ml
phcnyllactic acid. Inhibition was largely eliminated when these compounds were
brought to neutral pH. Nevertheless, slight inhibition was still evident in the case of
15 mg/ml phcnyllactic acid at neutral pH. This inhibition required further
investigation. Logically, further inhibition studies were to be carried out at higher
concentrations of phcnyllactic acid, this time in glass containers. Thus, 25 mg/ml
phcnyllactic acid, 25 mg/ml neutralized phcnyllactic acid and 25 mg/ml neutralized
lactic acid were added to growing cultures of E. coli DSMZ787 in glass cuvettes.
Bacterial plate counts were performed after growth.
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Figure 4.7 Growth characteristics ofE. coli DSMZ787 in the presence of
L-Phenyllactic acid, neutralized L-Phenyllactic acid and neutralized lactic acid in
glass.
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The data in Figure 4.7 indicates that 25mg/ml neutralized lactic acid docs not inhibit
bacteria growth. As expected, 25mg/ml phcnyllactic acid docs inhibit growth and is
clearly bacteriocidal, given the drop in cell count from 5.1 x l(/’CFU/ml to less than
lO^CFU/ml. Interestingly, 25mg/ml neutralized phcnyllactic acid clearly inhibits
growth, and is clearly bacteriostatic given that the cell count stays at lO^CFU/ml. Thus
the inhibitory properties of phcnyllactic acid are present at neutral pH. But the
inhibition is significantly enhanced at lower pH values. Thus, food-grade bacteria
producing this antimicrobial compound, would have a greater inhibitory effect against
pathogens in low pH foods.
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OD and the decrease in cell number, when inhibitory concentrations of LactiSAL are
present.

With the latter bacterium, cell lysis was evaluated in depth and was confirmed by
performing assays for Lactate dehydrogenase (LDH), an intracellular enzyme whose
detection in culture supernatants is an indicator of cell leakage. The enzyme is an
oxidoreductase, which catalyzes the interconversion of lactate and pyruvate. LDH is
the most frequently measured enzyme, to evaluate the presence of tissue or cell
damage or cell lysis. The control sample shows hardly any reduction in OD over the
three minutes (1.074 to 1.049), indicating minimal leakage of the enzyme LDH. The
test sample showed a significant reduction in OD over the three minutes (1.103 to
1.002), indicating presence of the enzyme LDH and thus leakage of cellular contents,
fhis result indicated that the lipoprotein LactiSAL caused cellular leakage.

Gram-negative bacteria were significantly more tolerant to LactiSAL than the Gram
positives. In the case of Escherichia coli, it was necessar>' to use LactiSAL at a level
of 3.0% or greater to inhibit all the Escherichia coli strains tested. As with the
Gram-positive bacteria, inhibitory levels of LactiSAL brought about cell lysis as
evidenced by a reduction in culture optical density and a concomitant reduction in cell
numbers. Similar results to this were obtained for the genus Salmonella and
Enterobacter. The genus of Helicobcter was more sensitive to LactiSAL, in that
concentrations of 0.67% and greater were completely inhibitory to all the Helicobcter
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strains tested. Growth of Helicobcter occured at 0.33% maximum. In the case of H.
pylori MS2583, concentrations of LactiSAL of 0.67% or greater brought about lysis
of bacterial cells, as evidenced by the reduction in optical density and the concomitant
reduction in viable cell numbers from 5.6 x lO^CFU/ml to 3.1 x 10‘^CFU/ml as
ascertained by plate count.

Evaluation of the effect of LactiSAL concentration on the strictly anaerobic bacterial
genera, namely Clostridium species and Bacteroides species, presented extra technical
considerations. For these experiments, spectrophotometer readings were taken in
paraffin oil-sealed broth cultures, in test-tubes tubes, using a specially adapted
test-tube holder in place of the cuvette holder for the spectrophotometer. In the case of
Clostridium difficile A'FCC43593, concentrations of LactiSAL of 0.1% or greater
brought about lysis of bacterial cells, as evidenced by the reduction in optical density,
and the concomitant reduction in viable cell numbers as ascertained by plate count.
For Bacteroides vulgatus DSMZ1447, concentrations of LactiSAL of 0.033% or
greater brought about lysis of bacterial cells as evidenced by the reduction in optical
density and the concomitant reduction in viable cell numbers.

Yeasts were also evaluated in the study. In the case of Candida, LactiSAL
concentrations of 0.133% and greater were completely inhibitory to all the Candida
albicans. Growth of Candida albican occuvQd at 0.133% maximum. Reduction in
optical density of the yeast culture in the presence of LactiSAL was also evident.
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indicating cellular lysis. Similar results to this were obtained for the Saccharomyces
cerevisiae.

At the time of execution of this work, LactiSAL was intended for ingestion by
humans. Thus, in this application, LactiSAL would be subjected to a range of
different pH environments as it would move through the gastrointestinal tract. The
data obtained indicated that 1% LactiSAL, (a lethal concentration for the test
bacterium Lactobacillus johnsonii) at all pHs (ranging from pH 1.0 to pH 9.0),
inhibited bacterial growth, bringing about an 8-log decrease in cell numbers. The
reduction in cell number brought about by the different LactiSAL pH-batches were
used to obtain an arbitrary activity value (ACFU) for the LactiSAL. Greatest
inhibitory activity was evident at pH 5 with a ACFU of 10^ (8-log decrease in cell
number). At pHs 1.0 and 9.0 the ACFU was approximately lO''. Thus, while extremes
in pFl do not inactivate LactiSAL, its antimicrobial efficacy is nevertheless reduced.
Thus, higher concentrations of LactiSAL would need to be employed to maintain
antimicrobial efficacy in pH-extreme environments. It was also of interest to ascertain
how long a activity cell needed to be exposed to LactiSAL to mediate cell death. The
results clearly showed that 5 minutes exposure to LactiSAL generally brought about a
100-fold reduction in cell numbers, while the 30 minute exposure generally brought
about up to a 10,000 fold reduction in cell numbers. Thus, duration of exposure to the
antimicrobial was important.
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The effect of LactiSAL on microbial inhabitants of porcine intestine was also
evaluated. This experiment involved the isolation of fresh porcine gastrointestinal
tract material containing typical viable porcine gut bacteria. Thus, 24-week old pigs
were slaughtered and their gastrointestinal tracts (GIT) removed and taken to the
laboratory immediately. Samples were removed from the GIT at four sites, namely the
stomach, the jejunum, the terminal ileum, and the descending colon where LactiSAL
could be added. The exposure to the LactiSAL at levels which were inhibitory for
Bifidobacterium, Lactobacillus and Clostridia, did not cause a reduction in numbers
of these bacteria. The apparent reduced efficacy of LactiSAL in the intestine
environment is thought to be due to enzymatic degradation of the LactiSAL in the
GIT material. Various lipases and proteases would still have been active in the
material. Acidic conditions of the GIT could also have reduced its efficacy. The fact
that the experiment showed similar results when done on three separate occasions
with three separate animals, reinforces this conclusion. Thus, LactiSAL would not be
effective as an antibacterial agent if consumed at the concentration used in the
experiment. In a follow-on project, this antimicrobial is being commercially
developed as a topical cream to eliminate Candida and other pathogenic organisms.

In the second section of the work, three novel low molecular weight antimicrobial
agents were studied. These were the cyclic dipeptides-Cyclo-(L-Leu-L-Pro);
cyclo-(L-Phe-L-Pro) and Phenyllactic Acid. These three antimicrobial agents are
naturally produced by Lactobacillus plantarum FSTL7. This bacterium and three
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additional ‘producer’ strains of Lactic acid Bacteria (LAB), which had also previously
implicated in antifungal activity to strain FST1.7, were evaluated against various
pathogenic bacteria. This work had not been carried out previously and thus all results
obtained were novel. All strains showed definite pH-independent zones on lawns of
the different pathogenic bacteria. The elimination of the pH effect was particularly
important in the case of the inhibitor Phenyllactic acid, since this substance is
fundamentally acidic, a property which is in itself antimicrobial. To recognise the
indigenous pH effect, the pHs of broths after complete growth of producer strains
(and a negative control strain) were recorded and these ranged from 5.09 to 5.34. It is
evident that the clear zones around the four producer strains were larger than the clear
zone around the negative control strain. I'he pH tolerance of target strains indicated
that all of the target (pathogenic) bacteria were not significantly inhibited by the
acid-related pH drop which resulted from growth of the producer strains. I’hus all four
producer strains inhibited all target bacteria and the inhibition was distinct from
acid-related inhibition.

Microtitre plate assays were conducted using a variety different target bacteria and
yeast, including Enterococcus, E. coli, MRSA, Enterobactor, Helicobacter, Listeria,
Salmonella and Candida. A variety of concentrations of the different inhibitors were
used. Phenyllactic acid concentrations of 5mg/ml and greater were completely
inhibitory to all target bacteria. As discussed above, it was also of interest to eliminate
the pH effect associated with this compound in this microtitre experiment. In the case
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of neutralized phenyllactic acid, while 5mg/ml did not inhibit growth, 15mg/ml was
slightly inhibitory. In the case of cyclic dipeptides, pH-neutralization was not
necessary. Cyclic dipeptide (LeuPro) concentrations of 20mg/ml and greater were
completely inhibitory to all target bacteria and yeast. Growth of target bacteria and
yeast did, however, occur at lOmg/ml. This data was derived from microtitre plate
assays, which involved using plastic microtitre dishes. One difficulty with this
methodology is that the antimicrobial compounds are known to have some affinity for
plastic. Thus, the experiments were repeated in glass (in larger volumes as dictated by
the available vessels). However, the results from the glass experiments were very
similar to the microtitre results. Fortunately, it was possible to also conduct plate
counts from the glass containers. Plate count data permitted getting a quantification of
the drop in bacterial numbers after exposure to the inhibitors. For example, 25mg/ml
phenyllactic acid was clearly bacteriocidal, given the drop in cell count from 5.1 x
lO^CFU/ml to less than lO^CFU/ml. The same concentration of neutralized
phenyllactic acid was only bacteriostatic, given that the cell count stayed at
lO^CFU/ml. Thus the inhibitory properties of phenyllactic acid were evident at neutral
pH, however, but the inhibition was significantly enhanced at lower pH values. Thus,
food-grade bacteria producing this antimicrobial compound would have a greater
inhibitory effect against pathogens in low pH foods, such as fermented foods. This
application will be evaluated in a follow-up study.
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In the case of the cyclic dipeptides, concentrations as high as 20 mg/ml (LeuPro) were
necessary to illicit a clear bacteriocidal effect. However, in the cytotoxicity work
executed, it was evident that this level is toxic for mammalian (BHK) cells. Cyclic
dipeptides could only be tolerated by the BHK cells at 5 mg/ml. This finding appears
to present a dilemma. Interestingly, though, the work of Strom (2002) on the
antifungal properties of these compounds, has indicated that they do have a
synergistic effect on each other, which is enhanced at low pH as discussed above. Thus
under certain conditions (whose establishment will be incorporated in a follow-up
project) these low molecular weight compounds may be inhibitory to bacterial
pathogens at levels which do not harm mammalian cells.
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Figure 4.8 Growth of E. coli DSMZ7H7 in the presence of lOmglml Cyclic dipeptide
LenPro (glass).

It can be seen from the data in Figure 4.8 that concentrations of 2()mg/ml LeuPro or
greater is bacteriocidal. This inhibition profile is studied in more detail below in
assays at intermediate concentrations of both dipeptides, LeuPro and PhePro.
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4.3.4.2 Inhibition of Exoli P1432 (0157) by dipeptide PhePro
Figure 4.9 Growth of E. coli PI432 in the presence of Cyclic dipeptide PhePro
(glass).

The data in Figure 4.9 indicates that the Cyclic dipeptidc PhePro inhibits growth,
causing a significant drop in cell numbers at a concentration of 2()mg/ml. Here, the
cell titre was reduced from 7.9 x lO^CFU/ml, to less than l()‘''CFU/ml. The drop in
optical density observed where 2()mg/ml Cyclic dipeptidc PhePro was included
suggests that cell lysis may be occurring at this concentration.
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Figure 4.10 Growth of K. coli PI 432 in the presence of Cyclic dipeptide LeuPro
(glass).

The data in Figure 4.10 indicates that Cyclic dipeptidc LeuPro, like the other
dipeptide, clearly inhibits bacterial growth. It brings about a reduction in cell number
at concentration of 2()mg/ml from 7.9 x lO^’CFU/ml to 1.8 x lO^’CFU/ml. The
accompanying drop in optical density observed where 2()mg/ml PhePro was included
suggests that cell lysis was also occurring with this dipeptidc.
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4.3.4.3 Yeast. Saccharomyces cerevisiae

It has been previously shown in Figs 4.3 and 4.4 that yeast and the other bacterial
genera are all inhibited by similar levels of phenyllactic acid. It’s important to
investigate if this is also the case for the dipeptides. Saccharomyces cerevisiae was
chosen as a target yeast. Other bacteria are tested in subsequent sections.

Figure 4.11 Growth of Saccharomyces cerevisiae DSMZl333 in the presence of
Cyclic dipeptide PhePro (glass).
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The data in Figure 4.11 indicates that Cyclic dipeptide PhePro inhibits yeast growth,
bringing about a reduction in cell number at concentration of 2()mg/ml, where the titre
was reduced from 1.9 x lO^CFU/ml, to 5.2 x lO^CFU/ml. The drop in optical density
observed where 2()mg/ml Cyclic dipeptide PhePro was included indicates that lysis is
probably occurring at this level.
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Figure 4.12 Growth of Saccharomyces cerevisiae DSMZl333 in the presence of
Cyclic dipeptide LeiiPro (glass).

The data in Figure 4.12 indicates that Cyclic dipeptide LeuPro inhibits yeast growth,
bringing about a reduction in cell number at concentration of 2()mg/ml where the titre
was reduced from 8.3 x l(/’CFU/ml to 1.0 x lO'^CFU/ml. The drop in optical density
observed where 20mg/ml Cyclic dipeptide LeuPro was included indicates that lysis is
probably occurring at this level.
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4.3.4.4 Salmonella enterica Newport T46

Figure 4.13 Growth of Salmonella enterica Newport T46 in the presence of Cyclic
dipeptide PhePro (glass).

The data in Figure 4.13 indicates that Cyclic dipeptide PhePro inhibits Salmonella
growth, bringing about a reduction in cell number at concentration of 2()mg/ml where
the titre was reduced from 2.0 x lO^CFU/ml to 4.8 x lO^CFU/ml. The drop in optical
density observed where 2()mg/ml Cyclic dipeptide PhePro was included indicates that
lysis is probably occurring at this level.
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Figure 4.14 Growth of Salmonella enterica Newport T46 in the presence of Cyclic
dipeptide LenPro (glass).

The data in Figure 4.14 indicates that Cyclic dipeptide IxuPro Inhibits Salmonella
growth, bringing about a reduction in cell number at concentration of 2()mg/ml where
the titre was reduced from 1.3 x lO^CFU/ml to 1.0 x lO^CFU/ml. The drop in optical
density observed where 2()mg/ml Cyclic dipeptide LcuPro was included indicates that
lysis is probably occurring at this level.
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4.3.4.5 Campylobacter jejuni DSMZ 4688

Figure 4.15 Growth of Campylobacter jejuni DSMZ46S8 in the presence of Cyclic
dipeptide PhePro (glass).

The data in Figure 4.15 indicates that Cyclic dipeptide PhePro inhibits Campylobacter
grnwth, bringing about a reduction in cell number at concentration of 2()mg/ml, where
the titre was reduced from 3.7 x lO^CFU/ml, to 1.3 x lO^CFU/ml. The drop in optical
density observed where 2()mg/ml Cyclic dipeptide PhePro was included indicates that
lysis is probably occurring at this level.
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Figure 4.16 Growth of Campylobacter jejuni DSMZ 4688 in the presence of Cyclic
dipeptide LeuPro (glass).

The data in Figure 4.16 indicates that Cyclic dipeptide LeuPro inhibits Campylobacter
growth, bringing about a reduction in cell number at concentration of 2()mg/ml, where
the titre was reduced from 1.0 x lO^CFU/ml, to 2.0 x 10^'CFU/ml. The drop in optical
density observed where 20mg/ml Cyclic dipeptide LeuPro was included indicates that
lysis is probably occurring at this level.
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4.3.4.6 Mycobacterium smegmatis

Figure 4.17 Growth of Mycobacterium smegmatis in the presence of Cyclic dipeptide
PheFro (glass).

The data in Figure 4.17 indicates that Cyclic dipeptide PhePro inhibits
Mycobacterium smegmatis growth, bringing about a reduction in cell number at
concentration of 2()mg/ml, where the titre was reduced from 3.4 x lO^’CFU/ml, to 1.5
X lO^CFU/ml. The drop in optical density observed where 2()mg/ml Cyclic dipeptide
PhePro was included indicates that lysis is probably occurring at this level.
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Figure 4.18 Growth of Mycobacterium smegmatis in the presence of Cyclic dipeptide
LeuPro (glass).

The data in Figure 4.18 indicates that Cyclic dipeptide LeuPro inhibits
Mycobacterium smegmatis growth, bringing about a reduction in cell number at
concentration of 2()mg/ml, where the titre was reduced from 9.2 x lO^’CFU/ml, to 1.0
X l(fCFU/ml. The drop in optical density observed where 2()mg/ml Cyclic dipeptide
LeuPro was included indicates that lysis is probably occurring at this level.
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4.3.4.7 Enterobacter sakazakii DSMZ 4485

Figure 4.19 Growth of Knterohacler sakazakii DSMZ 4485 in the presence of Cyclic
dipeptide PhePro (glass).

The data in Figure 4.19 indicates that Cyclic dipeptide PhePro Inhibits Enterobacter
sakazakii growth, bringing about a reduction in cell number at concentration of
2()mg/ml, where the titre was reduced from 3.9 x lO^’CFU/ml to 1.2 x lO^’CFU/ml. The
drop in optical density observed where 2()mg/ml Cyclic dipeptide PhePro was
included indicates that lysis is probably occurring at this level.
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Figure 4.20 Growth of Enlerohacter sakazakii DSMZ 4485 in the presence of Cyclic
dipeptide LeuPro (glass).

The data in Figure 4.20 indicates that Cyclic dipeptidc LeuPro inhibhs Enterohacter
sakazakii growth, bringing about a reduction in cell number at concentration of
2()mg/ml where the titre was reduced from 1.4 x lO^CFU/ml to 1.2 x l(/’CFU/ml. The
drop in optical density observed where 2()mg/ml Cyclic dipeptide LeuPro was
included, indicates that lysis is probably occurring at this level.
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4.3.4.8 Helicobacter pylori M2583

Figure 4.21 Growth of Helicobacter pylori M25S3 in the presence of Cyclic dipeptide
PhePro (glass).

The data in Figure 4.21 indicates that Cyclic dipeptidc PhePro inhibits Helicobacter
pylori gr(iwth, bringing about a reduction in cell number at concentration of 2()mg/ml,
where the titre was reduced from 1.4 x lO^CFU/ml to 3.0 x l()''CFU/ml. The drop in
optical density observed where 2()mg/ml Cyclic dipeptidc PhePro was included
indicates that lysis is probably occurring at this level.
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Figure 4.22 Growth of Helicobacter pylori M2583 in the presence of Cyclic dipeptide
LeuFro (glass).

The data in Figure 4.22 indicates that Cyclic dipeptide LeuPro inhibits Helicobacter
pylori growth, bringing about a reduction in cell number at concentration of 2()mg/ml,
where the titre was reduced from 8.1 x lO^’CFU/ml, to 2.1 x l(/’CFU/ml. The drop in
optical density observed where 2()mg/ml Cyclic dipeptide LeuPro was included
indicates that lysis is probably occurring at this level.
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4.3.4.9 Staphylococcus aureus M253472 (MRSA)

Figure 4.23 Growth of Staphylococcus aureus M253472 (MRSA) in the presence of
Cyclic dipeptide PhePro (glass).

The data in Figure 4.23 indicates that Cyclic dipeptide PhePro inhibits .Vm/;/2y/ococx7/.v
aureus growth, bringing about a reduction in cell number at concentration of 2()mg/ml,
where the titre was reduced from 8.5 x lO^’CFU/ml, to 2.1 x lO'^CFU/ml. The drop in
optical density observed where 2()mg/ml Cyclic dipeptide PhePro was included
indicates that lysis is probably occurring at this level.
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Figure 4.24 Growth of Staphylococcus aureus M253472 (MRSA) in the presence of
Cyclic dipeptide LeuPro (glass).

The data in Figure 4.24 indicates that Cyclic dipeptide LeuPro inhibits
Staphylococcus aureus growth, bringing about a reduction in cell number at
concentration of 2()mg/ml, where the titre was reduced from 1.6 x lO^CFU/ml to 2.0 x
lO^'CFU/ml. The drop in optical density observed where 20mg/ml Cyclic dipeptide
LeuPro was included indicates that lysis is probably occurring at this level.

158

4.3.4.10 Streptococcus pneumoniae DSMZ4688

Figure 4.25 Growth of Streptococcus pneumoniae DSMZ4688 in the presence of
Cyclic dipeptide PhePro (glass).

The data in figure 56 indicates that Cyclic dipeptidc PhePro \x\\\\h\{^ Streptococcus
pneumoniae growth, bringing about a reduction in cell number at concentration of
2()mg/ml, where the titre was reduced from 6.5 x l(/’CFU/ml, to 4.6 x lO^CFU/ml.
The drop in optical density observed where 2()mg/ml Cyclic dipeptidc PhePro was
included indicates that lysis is probably occurring at this level.
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Figure 4.26 Growth of Slreplococciis pneumoniae DSMZ4688 in the presence of
Cyclic dipeptide LeiiPro (glass).

The data in Figure 4.26 indicates that Cyclic dipeptide LcuPro mh'ihhs Streptococcus
pneumoniae growth, bringing about a reduction in cell number at concentration of
2()mg/ml where the titre was reduced from 6.5 x lO^’CFU/ml, to 7.0 x lO^’CFU/ml. The
drop in optical density observed where 2()mg/ml Cyclic dipeptide LcuPro was
included, indicates that lysis is probably occurring at this level.
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4.4 Cell toxicity studies.
Given that the antimicrobial agents arc known to inhibit fungi, which arc eukaryotic,
it was of interest to see if they caused damage to human cells. To investigate this,
each of the four producer strains (LAB) were streaked on blood agar.

4.4.1 Blood agar test
Cytotoxicity on blood agar is defined as lysis, which appears as clearing of the red
blood cells. Areas around LAB colonics were examined for clearing. All four
producer strains were capable of growth on the blood agar. As can be seen in Figure
4.27, the plates of Lactobacillus amylovoriis FSTl.la and Lactobacillus plantarum
FST1.7 had slight effect on blood agar, this was due solely to the low pH around
colonics. It is not uncommon for lactobacilli to cause slight yellowing of the blood
cells. Plates of Weissella cibaria FST1.31 and Lactobacillus plantarum FST1.9
showed no yellowing. Thus, these results arc difficult to interpret accurately. One of
the ongoing difficulties with using producer bacteria in antimicrobial assays is that
inhibition results arc frequently masked by a strong acid effect which is, in itself,
antimicrobial. To get a more accurate view of the effects of the low molecular weight
compounds on human cells, tissue cultures were used, in combination with purified
compounds. These cell toxicity studies with pure antimicrobial compounds carried arc
shown in Figure 4.28.
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Figure 4.27 Blood agar assay to streaked Lactobacillus plantarum FSTL7, Weissella

ciharia LSTL31, Lactobacillus plantarum FST1.9, Lactobacillus amylovorus FSTl.la
strains on BHI-blood agar.

Lactobacillus amylovorus FSTl.la

Lactobacillus plantarum FST1.9

Weissella cibaria FST1.31

Lactobacillus plantarum FST1.7
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4AJ, Cell culture cvtotoxicitv test

Baby hamster kidney (BHK) cells are fibroblast cells, and are anchorage-dependent in
that they grow in a monolayer on the bottom of tissue culture vessel. BHK cells were
treated with BHK medium containing different concentrations of L-phenyllactic acid,
neutralized L- phenyllactic acid and cyclic dipeptide LeuPro for 2 hours to observe the
effect of pure antimicrobial compounds on BHK cells (PhePro was not included at this
time due to the higher expense of this substance). The result of the exposure to the
compounds was seen following analysis using an inverted microscope 24 hours after
the exposure (Figures 4.28 and 4.29).

Figure 4.28 BHK tissue culture assays in the presence and absence of I.-phenyllactic
acid (a) BHK cells: negative control (h) BHK cells with -Phenyllactic acid 15 mglml
(c) BHK cells with I.-Phenyllactic acid ISmglml Adjusted to pH 6.0 (see overleaf).
(a) BHK cell negative control (24h)

Viable cells still adhering to the plastic with their characteristic spindle shape.
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(b) BHK cells with L-Phenyllactic acid 15 mg/ml (24h)

Cellular destruction characterized by floating spherical-shaped dead cells.

(c) BHK cells with L-Phenyllactic acid 15mg/ml Adjusted to pH 6.0

Viable cells still adhering to the plastic with their characteristic spindle shape.

The results of the different treatments of the BHK tissue cultures are indicated in
italics underneath each of the photomicrographs. Thus, when the pH effect is
eliminated with phenyllactic acid, the cytotoxic effect is also eliminated.
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Figure 4.29 BHK tissue culture assays in the presence and absence of Cyclic
dipeptide LeuPro (a) Cyclic dipeptide LeuPro 5mglml (b) Cyclic dipeptide LeuPro
10 mg!ml
(c) Cyclic dipeptide LeuPro lOmglml.

(a)Cyclic dipeptide LeuPro at 5mg/ml

Viable cells still adhering to the plastic with their characteristic spindle shape.

(b) Cyclic dipeptide LeuPro at lOmg/ml

Cellular destruction characterized by floating spherical-shaped dead cells.
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(c)Cyclic dipeptide LeuPro at 20mg/ml

Cellular destruction characterized by floatiiti^ spherical-shaped dead cells.

The data in Figure 4.29 indicates that the Cyclic dipeptide LxuPro is cytotoxic at
concentrations of lOmg/ml and higher. No cytotoxicity was evident at 5 mg/ml.
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Section 5

Conclusions
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The dramatic increase in antibiotic resistance in pathogenic bacteria in recent decades
has prompted research to find and characterize new antimicrobial agents to replace
increasingly redundant antibiotics. Several new antibiotic type drugs have emerged as
possible therapeutic alternatives, such as oxazolidinones, lipopeptides, streptogramins,
ketolides,

glycylcyclines,

expanded-spectrum

glycopeptides,

and

novel

fluoroquinolones (Cormican and Jones 1996, Gonzalez et al 2003, Raad et al 1998,
Woodford 2005). In addition to these, a wide variety of antimicrobial agents are still at
the research stage world-wide and some of these may find commercial applications in
the future.

The overall objective of this thesis was to evaluate the antimicrobial effects of four
novel broad-host-range antimicrobial agents. The first of these was a milk-derived
lipoprotein developed by Westgate Biologicals with the support of Enterprise Ireland.
Initially, this substance was available in powder-form , which was designated
ImmunoSAL. Subsequently , it became available as a high activity concentrate liquid ,
derived from a consistent production process , which involved relevant enzymatic
treatment of milk. The resultant concentrated antimicrobial had the consistency of a
thick yoghurt and was designated LactiSAL. This was used throughout the study,
where several bacteria and yeasts were used to provide more specific information, for
antimicrobial activity of the milk-derived lipoprotein. Generally, the work was
restricted to the requirements of Westgate Biologicals and the Enterprise Ireland
program of work.
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All target microorganisms were plated on their respective agar media, containing
different concentrations of LactiSAL. Each culture was triple streaked for clear
isolated colonies. Diameters of colonies were measured in mm, and the results of each
of the platings were recorded. Subsequently, the growth rates of the strains were
measured in the absence and presence of different lethal and sub-lethal concentrations
of LactiSAL. Within each genus, one strain was selected for challenge during a
standard growth curve in liquid medium, using different concentrations of the
antimicrobial. Typically, each genus was challenged with 6 different concentrations of
LactiSAL, ranging from lethal to sublethal amounts.

In the case of the genus Lactobacillus, LactiSAL concentrations of 0.33% and greater
were completely inhibitory to all the Lactocacillus species tested in the experimental
work. Growth of Lactobacillus occurred at 0.2% LactiSAL maximum, albeit
sub-optimally. The data obtained for this genus indicated that higher concentrations
caused a significant drop in cell numbers, where (at 0.4%) the titre was reduced from
4.6

X

10^ to 4.0

X

10^. The drop in numbers (and also optical density), over the

relatively short time period, indicated that cell lysis of lactobacilli was occurring. In
the case of Bifidobacterium, this genus was more sensitive than Lactobacillus in that
LactiSAL concentrations of 0.2% and greater were completely inhibitory to all
bifidobacteria tested. Growth of Bifidobacterium occured at 0.133% maximum. The
data obtained indicated that LactiSAL inhibited growth, brought about a slight
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reduction in cell numbers at 0.1%, and caused a significant drop in cell numbers at
0.2%, where the titre was reduced from 9.2 x 10^ to 2.8 x 10^. The drop in optical
density and titre when 0.2% LactiSAL was included indicated (similarly to
Lactobacillus) that cell lysis was occurring at this level. Similar results to this (in
terms of LactiSAL concentration) were obtained for the genus Bacillus. The genus
Enterococcus was less sensitive to LactiSAL in that concentrations of 0.4% and
greater were necessary to completely inhibit all the Enterococcus strains tested.
Growth of Enterococcus occured at 0.33% maximum. The data obtained, indicated
that LactiSAL inhibited growth and caused a significant drop in cell numbers at 0.4%,
where the titre was reduced from 2.0 x 10^ to 4.2 x 10^. Similar results to this (in
terms of LactiSAL concentration) were obtained for Staphylococcus. As with
Lactobacillus and Bifidobacterium, cell lysis was also evident when LactiSAL was
present at inhibitory levels. The genera Streptococcus and Lactococcus were
significantly more sensitive to LactiSAL than either of the above genera. In the case
Streptococcus infantis DSMZ12492, concentrations of LactiSAL of 0.1% or greater
were seen to bring about lysis of bacterial cells as evidenced by the reduction in
optical density and the concomitant reduction in viable cell numbers as ascertained by
plate count. Furthermore, the genus Lactococcus showed similar sensitivity
properties. LactiSAL concentrations of 0.1% and greater were completely inhibitory
to all the Lactococcus strains. Growth of Lactococcus occured at 0.067% LactiSAL
maximum. Lactococcus lactis was confirmed to be highly sensitive to LactiSAL. Cell
lysis was also evident, as with previous Gram-positive bacteria from the decrease in
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